


**CUMULATIVE
SUPPLEMENT 3
MARCH 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Cumulative Supplement 3

March 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement.....	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend.....	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List.....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution.....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists.....	A-1
B. Patent and Exclusivity Terms.....	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

CUMULATIVE SUPPLEMENT 3
March 2015

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic

Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352			
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)			
MULTISOURCE	13578 (84.1%)	13744 (84.1%)			
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)			
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)			
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	13	22			
NUMBER OF APPLICANTS	927	935			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL
FIORICET

@ ACTAVIS LABS UT INC 325MG; 50MG; 40MG A088616 001 Nov 09, 1984 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
FIORICET W/ CODEINE

AB + ACTAVIS LABS UT INC 325MG; 50MG; 40MG; 30MG N020232 001 Jul 30, 1992 Jan CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MIKART 325MG; 2.5MG A040846 001 Jun 09, 2010 Feb CTEC

NORCO ACTAVIS LABS FL INC 325MG; 2.5MG A040148 004 Jul 07, 2014 Feb NEWA

AA 325MG; 5MG A040148 005 Jul 07, 2014 Feb NEWA

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS
ACETYLCYSTEINE

>A> AP AKORN INC 6GM/30ML (200MG/ML) A203173 001 Mar 24, 2015 Mar NEWA

ALBUTEROL SULFATE

>A> POWDER, METERED; INHALATION

>A> PROAIR RESPICLICK

>A> + TEVA BRANDED PHARM EQ 0.090MG BASE/INH N205636 001 Mar 31, 2015 Mar NEWA

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE

@ WOCKHARDT LTD 10MG A090221 001 Aug 10, 2012 Feb DISC

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

>A> AB NATCO PHARMA LTD 0.25MG A200739 001 Apr 15, 2015 Mar NEWA

>A> AB 0.5MG A200739 002 Apr 15, 2015 Mar NEWA

>A> AB 1MG A200739 003 Apr 15, 2015 Mar NEWA

>A> AB 2MG A200739 004 Apr 15, 2015 Mar NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HYDROCHLORIDE

AB BANNER LIFE SCIENCES 100MG A078720 001 May 29, 2008 Jan CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE

>D> @ ASTRAZENECA EQ 50MG BASE/ML A063167 001 Dec 14, 1995 Mar CAHN

>D> @ EQ 250MG BASE/ML A063169 001 Dec 14, 1995 Mar CAHN

>A> @ IGI LABS INC EQ 50MG BASE/ML A063167 001 Dec 14, 1995 Mar CAHN

>A> @ EQ 250MG BASE/ML A063169 001 Dec 14, 1995 Mar CAHN

AMINO ACIDS

INJECTABLE; INJECTION
BRANCHAMIN 4% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 4% (4GM/100ML) N018684 001 Sep 28, 1984 Feb DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 3.5%; 51MG/100ML; 131MG/100ML; 218MG/100ML; 35MG/100ML N020177 001 Oct 23, 1995 Feb DISC

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

>A>	AB	CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011	Mar	CAHN
>A>	AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Mar	CAHN
>D>	AB	SECAN PHARMS	EQ 5MG BASE	A090752	001	Apr 15, 2011	Mar	CAHN
>D>	AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Mar	CAHN

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

		SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Jan	NEWA
			EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Jan	NEWA
	+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Jan	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

>A>	AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar	NEWA
>A>	AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar	NEWA
>A>	AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar	NEWA
>A>	AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar	NEWA
>A>	AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar	NEWA
>A>	AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar	NEWA
>A>	AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar	NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

		NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan	NEWA
--	--	-------------------	----------------	---------	-----	--------------	-----	------

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

>D>		ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar	CTNA
>D>	+		10MG	A200166	002	Aug 09, 2012	Mar	CTNA
>A>		EVEKEO						
>A>		ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar	CTNA
>A>	+		10MG	A200166	002	Aug 09, 2012	Mar	CTNA

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

>A>		@ KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011	Mar	CAHN
>D>		@ KUDCO IRELAND	1MG	A091331	001	Jan 05, 2011	Mar	CAHN

ARGATROBAN

INJECTABLE;IV (INFUSION)

ARGATROBAN

>A>	AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Mar	NEWA
-----	----	--------------------	------------------------	---------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

		CAPSULE;ORAL							
		FIORINAL							
AA	+	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jan	CAHN	
		TABLET;ORAL							
		FIORINAL							
	@	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan	CAHN	

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

		CAPSULE;ORAL							
		FIORINAL W/CODEINE							
AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Jan	CAHN	

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

		TABLET;ORAL							
		NORGESIC							
>D>									
>D>	AB	MEDICIS	385MG;30MG;25MG	N013416	003	Oct 27, 1982	Mar	DISC	
>A>		@	385MG;30MG;25MG	N013416	003	Oct 27, 1982	Mar	DISC	
		NORGESIC FORTE							
>D>	AB	+	MEDICIS	770MG;60MG;50MG	N013416	004	Oct 27, 1982	Mar	DISC
>A>		@	770MG;60MG;50MG	N013416	004	Oct 27, 1982	Mar	DISC	
		ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE							
>D>	AB		SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar	CTEC
>A>				385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar	CTEC
>D>	AB			770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar	CTEC
>A>		+		770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar	CTEC

ASPIRIN; OXYCODONE HYDROCHLORIDE

		TABLET;ORAL							
		OXYCODONE AND ASPIRIN							
>A>	AA	ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar	CAHN	
>D>	AA	WATSON LABS	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar	CAHN	

ATAZANAVIR SULFATE; COBICISTAT

		TABLET;ORAL							
		EVOTAZ							
	+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015	Jan	NEWA	

ATENOLOL

		TABLET;ORAL							
		TENORMIN							
AB		ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb	CAHN	
AB			50MG	N018240	001		Feb	CAHN	
AB	+		100MG	N018240	002		Feb	CAHN	

ATENOLOL; CHLORTHALIDONE

		TABLET;ORAL							
		TENORETIC 100							
AB	+	ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb	CAHN	
		TENORETIC 50							
AB		ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb	CAHN	

ATORVASTATIN CALCIUM

		TABLET;ORAL							
		ATORVASTATIN CALCIUM							
>A>	AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar	CAHN	
>A>	AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar	CAHN	
>A>	AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar	CAHN	
>A>	AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar	CAHN	
>D>	AB	KUDCO IRELAND	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar	CAHN	
>D>	AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar	CAHN	
>D>	AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar	CAHN	
>D>	AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar	CAHN	

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

		TABLET;ORAL							
		ATOVAQUONE AND PROGUANIL HYDROCHLORIDE							
>A>	AB	GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar	NEWA	

ATRACURIUM BESYLATEINJECTABLE; INJECTION
ATRACURIUM BESYLATE

>A>	AP	AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar	NEWA
		ATRACURIUM BESYLATE PRESERVATIVE FREE						
>A>	AP	AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar	NEWA

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDETABLET; ORAL
MOTOFEN

+	SEBELA IRELAND LTD	0.025MG; 1MG	N017744	002			Feb	CAHN
	MOTOFEN HALF-STRENGTH							
@	SEBELA IRELAND LTD	0.025MG; 0.5MG	N017744	001			Feb	CAHN

AVIBACTAM SODIUM; CEFTAZIDIMEPOWDER; IV (INFUSION)
AVYCAZ

+	CEREXA INC	EQ 0.5GM BASE; 2GM/VIAL	N206494	001	Feb 25, 2015	Feb	NEWA
---	------------	-------------------------	---------	-----	--------------	-----	------

BENZAEPRIIL HYDROCHLORIDE

TABLET; ORAL

BENZAEPRIIL HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Jan	CAHN
AB		10MG	A076820	002	Feb 03, 2006	Jan	CAHN
AB		20MG	A076820	003	Feb 03, 2006	Jan	CAHN
AB		40MG	A076820	004	Feb 03, 2006	Jan	CAHN

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	APOTEX INC	100MG	A091310	001	Jan 16, 2015	Jan	NEWA
AA		200MG	A091310	002	Jan 16, 2015	Jan	NEWA
AA	BANNER LIFE SCIENCES	100MG	A081297	001	Jan 29, 1993	Jan	CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan	CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ONEXTON

+	DOW PHARM	3.75%; EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan	CRLD
---	-----------	---------------------	---------	-----	--------------	-----	------

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

>A>	AA	NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Mar	NEWA
>A>	AA		1MG	A204713	002	Apr 14, 2015	Mar	NEWA
>A>	AA		2MG	A204713	003	Apr 14, 2015	Mar	NEWA

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

>D>	AA	EMCURE USA	5MG	A091256	001	May 04, 2010	Mar	CAHN
>D>	AA		10MG	A091256	002	May 04, 2010	Mar	CAHN
>D>	AA		25MG	A091256	003	May 04, 2010	Mar	CAHN
>D>	AA		50MG	A091256	004	May 04, 2010	Mar	CAHN
>A>	AA	HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Mar	CAHN
>A>	AA		10MG	A091256	002	May 04, 2010	Mar	CAHN
>A>	AA		25MG	A091256	003	May 04, 2010	Mar	CAHN
>A>	AA		50MG	A091256	004	May 04, 2010	Mar	CAHN
	AA	LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Feb	CMFD
	AA		50MG	A040677	001	Mar 27, 2008	Feb	CMFD
		DUVOID						
AA		WELLSPRING PHARM	10MG	A086262	001		Jan	CMFD

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

@	BANNER LIFE SCIENCES	75MG	A203174	001	Aug 12, 2014	Jan	CAHN
---	----------------------	------	---------	-----	--------------	-----	------

BIMATOPROSTSOLUTION/DROPS;OPHTHALMIC
BIMATOPROST

>D>	AT	+	LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Mar	CTEC
>A>		+		0.03%	A203991	001	Feb 20, 2015	Mar	CTEC
	AT	+		0.03%	A203991	001	Feb 20, 2015	Feb	NEWA

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM

AT1			PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan	NEWA
-----	--	--	-------------	---------------	---------	-----	--------------	-----	------

BUDESONIDESPRAY, METERED;NASAL
BUDESONIDE

>D>	AB		APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Mar	CTEC
>A>				0.032MG/INH	A078949	001	May 12, 2014	Mar	CTEC

BUPRENORPHINE HYDROCHLORIDETABLET;SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

AB			ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb	NEWA
AB				EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb	NEWA
AB			MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb	NEWA
AB				EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb	NEWA

BUPROPION HYDROBROMIDETABLET, EXTENDED RELEASE;ORAL
APLENZIN

			VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
				348MG	N022108	002	Apr 23, 2008	Feb	CAHN
		+		522MG	N022108	003	Apr 23, 2008	Feb	CAHN

					N022108	001	Apr 23, 2008	Feb	CAHN
					N022108	002	Apr 23, 2008	Feb	CAHN
					N022108	003	Apr 23, 2008	Feb	CAHN

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

>D>	AB2		ACTAVIS	150MG	A077475	001	Mar 12, 2008	Mar	CAHN
>A>	AB2		SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar	CAHN

CALCITONIN SALMONINJECTABLE;INJECTION
CALCITONIN-SALMON

>D>		@	ASTRAZENECA	200 IU/ML	A073690	001	Apr 14, 1995	Mar	CAHN
>A>		@	IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995	Mar	CAHN

CALCITRIOLCAPSULE;ORAL
CALCITRIOL

AB			BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013	Jan	CAHN
AB				0.5MCG	A091174	002	May 24, 2013	Jan	CAHN
AB			STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014	Jan	CAHN
AB				0.5MCG	A091356	002	Dec 12, 2014	Jan	CAHN

CALCIUM ACETATETABLET;ORAL
CALCIUM ACETATE

AB			ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan	NEWA
----	--	--	----------------------	------------------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDEINJECTABLE;INJECTION
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+			GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan	CPOT
---	--	--	--------------------	---	---------	-----	--------------	-----	------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@			GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan	CPOT
---	--	--	--------------------	--	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan	CPOT
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan	CPOT
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER							
@	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan	CPOT
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER							
@	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan	CPOT
PRISMASOL BK 0/0 IN PLASTIC CONTAINER							
@	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan	CPOT
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan	CPOT
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan	CPOT
PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER							
@	GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan	CPOT

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
+	GAMBRO LUNDIA	N/A/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan	NEWA
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
+	GAMBRO LUNDIA	3.68GM/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan	NEWA

INJECTABLE; INJECTION

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

GM/1000ML

; 3.09GM/1000ML; 6.34GM/1000ML; 0.187

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

>D> PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

>D> + BAXTER HLTHCARE 37MG/100ML; 5GM/100ML; 30MG/100ML; 11 N017390 001 Mar DISC
9MG/100ML; 161MG/100ML; 94MG/100ML; 1
38MG/100ML>A> @ 37MG/100ML; 5GM/100ML; 30MG/100ML; 11 N017390 001 Mar DISC
9MG/100ML; 161MG/100ML; 94MG/100ML; 1
38MG/100MLCALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

>D> PLASMA-LYTE R IN PLASTIC CONTAINER

>D> + BAXTER HLTHCARE 36.8MG/100ML; 30.5MG/100ML; 74.6MG/1 N017438 001 Mar DISC
00ML; 640MG/100ML; 496MG/100ML; 89.6M
G/100ML>A> @ 36.8MG/100ML; 30.5MG/100ML; 74.6MG/1 N017438 001 Mar DISC
00ML; 640MG/100ML; 496MG/100ML; 89.6M
G/100MLCALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+ GAMBRO LUNDIA N/A/1000ML; 3.05GM/1000ML; 0.314GM/1 N207026 002 Jan 13, 2015 Feb CAIN
000ML; 2.21GM/1000ML; 6.95GM/1000ML;
0.187GM/1000ML (5000ML)

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO LUNDIA 3.68GM/1000ML; 3.05GM/1000ML; 0.314G N207026 001 Jan 13, 2015 Feb CAIN
M/1000ML
; 3.09GM/1000ML; 6.34GM/1000ML; 0.187CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB MACLEODS PHARMS LTD 16MG; 12.5MG A204100 001 Feb 27, 2015 Feb NEWA
AB 32MG; 12.5MG A204100 002 Feb 27, 2015 Feb NEWA
AB 32MG; 25MG A204100 003 Feb 27, 2015 Feb NEWACARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

IMPAX LABS INC

23.75MG; 95MG

N203312 001 Jan 07, 2015 Jan NEWA

36.25MG; 145MG

N203312 002 Jan 07, 2015 Jan NEWA

48.75MG; 195MG

N203312 003 Jan 07, 2015 Jan NEWA

+ 61.25MG; 245MG N203312 004 Jan 07, 2015 Jan NEWA

SUSPENSION; ENTERAL

DUOPA

+ ABBVIE INC

4.63MG/ML; 20MG/ML

N203952 001 Jan 09, 2015 Jan NEWA

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP FACTA FARMA

EQ 1GM BASE/VIAL

A063207 001 Dec 27, 1991 Jan CAHN

AP EQ 10GM BASE/VIAL A063209 001 Dec 27, 1991 Jan CAHN

AP + EQ 20GM BASE/VIAL A063209 002 Apr 30, 1999 Jan CAHN

AP EQ 500MG BASE/VIAL A063214 001 Dec 27, 1991 Jan CAHN

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

>D> @ ASTRAZENECA

EQ 1GM BASE/VIAL

N050588 001 Dec 27, 1985 Mar CAHN

>D> @ EQ 2GM BASE/VIAL N050588 002 Dec 27, 1985 Mar CAHN

>D> @ EQ 10GM BASE/VIAL N050588 003 Apr 25, 1988 Mar CAHN

>A> @ IGI LABS INC EQ 1GM BASE/VIAL N050588 001 Dec 27, 1985 Mar CAHN

>A> @ EQ 2GM BASE/VIAL N050588 002 Dec 27, 1985 Mar CAHN

>A> @ EQ 10GM BASE/VIAL N050588 003 Apr 25, 1988 Mar CAHN

INJECTABLE; INJECTION

CEFOTAN IN PLASTIC CONTAINER

>D>	@ ASTRAZENECA	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar CAHN
>D>	@	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar CAHN
>A>	@ IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar CAHN
>A>	@	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar CAHN

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

CEFTRIAZONE

AP	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan CAHN
	INJECTABLE; INTRAMUSCULAR, INTRAVENOUS					
	CEFTRIAZONE					
	@ FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan CAHN
	@	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan CAHN

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

AP	FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan CAHN
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan CAHN
	INJECTABLE; INTRAMUSCULAR, INTRAVENOUS					
	CEFUROXIME SODIUM					
AB	FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan CAHN

CELECOXIB

CAPSULE; ORAL

CELECOXIB

AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan NEWA
AB		200MG	A078857	003	Feb 11, 2015	Jan NEWA
AB		400MG	A078857	004	Feb 11, 2015	Jan NEWA
AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
AB		100MG	A200562	002	Feb 11, 2015	Jan NEWA
AB		200MG	A200562	003	Feb 11, 2015	Jan NEWA
AB		400MG	A200562	004	Feb 11, 2015	Jan NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA	TRIS PHARMA INC	4MG/5ML; 5MG/5ML	A206438	001	Jan 27, 2015	Jan NEWA
	VITUZ					
AA	+ CYPRESS PHARM	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Jan CFTG

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

	+ EUROHLTH INTL SARL	25MG/ML	A083329	001		Feb CAHN
--	----------------------	---------	---------	-----	--	----------

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

>D>	@ MUTUAL PHARM	50MG	A089286	001	Jul 21, 1986	Mar CMFD
>A>	AB	50MG	A089286	001	Jul 21, 1986	Mar CMFD

>A> CHOLIC ACID

>A> CAPSULE; ORAL

>A> CHOLBAM

>A>	ASKLEPION PHARMS LLC	50MG	N205750	001	Mar 17, 2015	Mar NEWA
>A>	+	250MG	N205750	002	Mar 17, 2015	Mar NEWA

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb NEWA
	CISATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb NEWA
AP		EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb NEWA

CLARITHROMYCIN

	TABLET, EXTENDED RELEASE;ORAL						
	BIAXIN XL						
	@ ABBVIE	500MG		N050775	001	Mar 03, 2000	Jan DISC
	CLARITHROMYCIN						
AB	+ TEVA	500MG		A065154	001	May 18, 2005	Jan CRLD

CLINDAMYCIN PHOSPHATE

	INJECTABLE;INJECTION						
	CLINDAMYCIN PHOSPHATE						
>D>	@ ASTRAZENECA	EQ 150MG BASE/ML		A062928	001	Feb 13, 1989	Mar CAHN
>A>	@ IGI LABS INC	EQ 150MG BASE/ML		A062928	001	Feb 13, 1989	Mar CAHN
	SOLUTION;TOPICAL						
	CLINDAMYCIN PHOSPHATE						
	@ BOCA PHARMA LLC	EQ 1% BASE		A062944	001	Jan 11, 1989	Jan CAHN

CLOBETASOL PROPIONATE

	OINTMENT;TOPICAL						
	CLOBETASOL PROPIONATE						
AB	G AND W LABS INC	0.05%		A074089	001	Feb 16, 1994	Feb CAHN
	SOLUTION;TOPICAL						
	CLOBETASOL PROPIONATE						
>D>	@ G AND W LABS INC	0.05%		A074331	001	Dec 15, 1995	Mar CMFD
>A>	AT	0.05%		A074331	001	Dec 15, 1995	Mar CMFD

CLONIDINE

	FILM, EXTENDED RELEASE;TRANSDERMAL						
	CLONIDINE						
>A>	AB ACTAVIS LABS UT INC	0.1MG/24HR		A090873	001	May 06, 2014	Mar CAHN
>A>	AB	0.2MG/24HR		A090873	002	May 06, 2014	Mar CAHN
>A>	AB	0.3MG/24HR		A090873	003	May 06, 2014	Mar CAHN
>D>	AB WATSON LABS INC	0.1MG/24HR		A090873	001	May 06, 2014	Mar CAHN
>D>	AB	0.2MG/24HR		A090873	002	May 06, 2014	Mar CAHN
>D>	AB	0.3MG/24HR		A090873	003	May 06, 2014	Mar CAHN

COBICISTAT; DARUNAVIR ETHANOLATE

	TABLET;ORAL						
	PREZCOBIX						
	+ JANSSEN PRODS	150MG;EQ 800MG BASE		N205395	001	Jan 29, 2015	Jan NEWA

CODEINE SULFATE

	SOLUTION;ORAL						
	CODEINE SULFATE						
	@ ROXANE	30MG/5ML		N202245	001	Jun 30, 2011	Jan DISC

COLCHICINE

	CAPSULE;ORAL						
	MITIGARE						
	HIKMA INTL PHARMS	0.6MG		N204820	001	Sep 26, 2014	Jan CAHN

CYANOCOBALAMIN

	INJECTABLE;INJECTION						
	CYANOCOBALAMIN						
	@ EUROHLTH INTL SARL	1MG/ML		A080515	002		Feb CAHN

DABRAFENIB MESYLATE

	CAPSULE;ORAL						
	TAFINLAR						
>D>	GLAXOSMITHKLINE	EQ 50MG BASE		N202806	001	May 29, 2013	Mar CAHN
>D>	+	EQ 75MG BASE		N202806	002	May 29, 2013	Mar CAHN
>A>	NOVARTIS PHARMS CORP	EQ 50MG BASE		N202806	001	May 29, 2013	Mar CAHN
>A>	+	EQ 75MG BASE		N202806	002	May 29, 2013	Mar CAHN

DARIFENACIN HYDROBROMIDE

	TABLET, EXTENDED RELEASE;ORAL						
	DARIFENACIN HYDROBROMIDE						
>A>	ANCHEN PHARMS	EQ 7.5MG BASE		A091190	001	Mar 13, 2015	Mar NEWA
>A>	AB	EQ 15MG BASE		A091190	002	Mar 13, 2015	Mar NEWA
	ENABLEX						
>D>	WARNER CHILCOTT LLC	EQ 7.5MG BASE		N021513	001	Dec 22, 2004	Mar CFTG

TABLET, EXTENDED RELEASE;ORAL
ENABLEX

>A>	AB		EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar	CFTG
>D>	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar	CFTG
>A>	AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar	CFTG

DECITABINE

INJECTABLE; INTRAVENOUS
DACOGEN

AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan	CAHN
----	---	---------------------	-----------	---------	-----	--------------	-----	------

DEFERASIROX

>A>			TABLET;ORAL					
>A>			JADENU					
>A>		NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Mar	NEWA
>A>			180MG	N206910	002	Mar 30, 2015	Mar	NEWA
>A>	+		360MG	N206910	003	Mar 30, 2015	Mar	NEWA

DESMOPRESSIN ACETATE

TABLET;ORAL
DDAVP

AB		FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan	CAHN
AB	+		0.2MG	N019955	002	Sep 06, 1995	Jan	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

>A>		@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar	CAHN
AP	+		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb	CAHN
>D>		@ HIKMA MAPLE	EQ 4MG PHOSPHATE/ML	A084282	001		Mar	CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
MAXITROL

>A>	AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Mar	CAHN
>D>	AT	+	FALCON PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Mar	CAHN

SUSPENSION/DROPS;OPHTHALMIC
MAXITROL

>A>	AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Mar	CAHN
>D>	AT	+	FALCON PHARMS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Mar	CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
PRECEDEX

		HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan	NEWA
--	--	---------	--------------------------------------	---------	-----	--------------	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

>D>			PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER					
>D>		BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451	001		Mar	DISC
>A>		@	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451	001		Mar	DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION
MD-76R

AP	+	LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989	Feb	CAHN
			SOLUTION;ORAL, RECTAL					
			MD-GASTROVIEW					
AA		LIEBEL-FLARSHEIM	66%;10%	A087388	001		Jan	CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

TENUATE

>A>	AA	+	ACTAVIS LABS UT INC	25MG	N011722	002		Mar	CAHN
>D>	AA	+	WATSON PHARMS	25MG	N011722	002		Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

TENUATE DOSPAN

>A>	AB	+	ACTAVIS LABS UT INC	75MG	N012546	001		Mar	CAHN
>D>	AB	+	WATSON PHARMS	75MG	N012546	001		Mar	CAHN

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

>D>	AB		EMCURE PHARMS USA	500MG	A202845	001	Mar 08, 2012	Mar	CAHN
>A>	AB		HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012	Mar	CAHN

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP			EUROHLTH INTL SARL	0.25MG/ML	A083391	001		Feb	CAHN
----	--	--	--------------------	-----------	---------	-----	--	-----	------

TABLET; ORAL

DIGOXIN

AB			MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jan	CTEC
AB				0.25MG	A040282	002	Dec 23, 1999	Jan	CTEC
AB			SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Feb	CMFD
AB				0.25MG	A076363	002	Jan 31, 2003	Feb	CMFD

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILACOR XR

>A>		@	ACTAVIS LABS UT INC	120MG	N020092	001	May 29, 1992	Mar	CAHN
>A>		@		180MG	N020092	002	May 29, 1992	Mar	CAHN
>A>		@		240MG	N020092	003	May 29, 1992	Mar	CAHN
>D>		@	WATSON LABS	120MG	N020092	001	May 29, 1992	Mar	CAHN
		@		120MG	N020092	001	May 29, 1992	Feb	DISC
>D>		@		180MG	N020092	002	May 29, 1992	Mar	CAHN
		@		180MG	N020092	002	May 29, 1992	Feb	DISC
>D>		@		240MG	N020092	003	May 29, 1992	Mar	CAHN
		@		240MG	N020092	003	May 29, 1992	Feb	DISC

DILTIAZEM HYDROCHLORIDE

AB2	+		MYLAN	240MG	A075124	001	Mar 18, 1998	Feb	CRLD
			TIAZAC						
AB4			VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995	Feb	CAHN
AB4				180MG	N020401	002	Sep 11, 1995	Feb	CAHN
AB4				240MG	N020401	003	Sep 11, 1995	Feb	CAHN
AB4				300MG	N020401	004	Sep 11, 1995	Feb	CAHN
AB4				360MG	N020401	005	Sep 11, 1995	Feb	CAHN
AB4	+			420MG	N020401	006	Oct 16, 1998	Feb	CAHN

DISULFIRAM

TABLET; ORAL

DISULFIRAM

AB			MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb	NEWA
AB				500MG	A203916	002	Mar 04, 2015	Feb	NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

>D>		@	ASTRAZENECA	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar	CAHN
>A>		@	IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar	CAHN

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB			HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan	NEWA
AB				10MG	A203034	002	Jan 30, 2015	Jan	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC

>D>		FOREST LABS INC	10MG;14MG	N206439	001	Dec 23, 2014	Mar CAHN
>D>	+		10MG;28MG	N206439	002	Dec 23, 2014	Mar CAHN
>A>		FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Mar CAHN
>A>	+		10MG;28MG	N206439	002	Dec 23, 2014	Mar CAHN

DOPAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE

>D>	@	ASTRAZENECA	40MG/ML	A070087	001	Oct 23, 1985	Mar CAHN
>D>	@		40MG/ML	N018656	001	Jun 28, 1983	Mar CAHN
>D>	@		80MG/ML	A070089	001	Oct 23, 1985	Mar CAHN
>D>	@		80MG/ML	A070090	001	Oct 23, 1985	Mar CAHN
>D>	@		80MG/ML	A070091	001	Oct 23, 1985	Mar CAHN
>D>	@		160MG/ML	A070092	001	Oct 23, 1985	Mar CAHN
>D>	@		160MG/ML	A070093	001	Oct 23, 1985	Mar CAHN
>D>	@		160MG/ML	A070094	001	Oct 23, 1985	Mar CAHN
>A>	@	IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985	Mar CAHN
>A>	@		40MG/ML	N018656	001	Jun 28, 1983	Mar CAHN
>A>	@		80MG/ML	A070089	001	Oct 23, 1985	Mar CAHN
>A>	@		80MG/ML	A070090	001	Oct 23, 1985	Mar CAHN
>A>	@		80MG/ML	A070091	001	Oct 23, 1985	Mar CAHN
>A>	@		160MG/ML	A070092	001	Oct 23, 1985	Mar CAHN
>A>	@		160MG/ML	A070093	001	Oct 23, 1985	Mar CAHN
>A>	@		160MG/ML	A070094	001	Oct 23, 1985	Mar CAHN

DOXEPIIN HYDROCHLORIDECAPSULE;ORAL
DOXEPIIN HYDROCHLORIDE

AB	+	MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan CRLD
	+	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan CRLD

CREAM;TOPICAL
ZONALON

>A>	+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar CAHN
>D>	+	FOUGERA PHARMS	5%	N020126	001	Apr 01, 1994	Mar CAHN

DROPERIDOLINJECTABLE; INJECTION
DROPERIDOL

>D>	@	ASTRAZENECA	2.5MG/ML	A072019	001	Oct 19, 1988	Mar CAHN
>D>	@		2.5MG/ML	A072020	001	Oct 19, 1988	Mar CAHN
>D>	@		2.5MG/ML	A072021	001	Oct 19, 1988	Mar CAHN
>A>	@	IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar CAHN
>A>	@		2.5MG/ML	A072020	001	Oct 19, 1988	Mar CAHN
>A>	@		2.5MG/ML	A072021	001	Oct 19, 1988	Mar CAHN

ECONAZOLE NITRATECREAM;TOPICAL
ECONAZOLE NITRATE

>D>	AB	+	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar CRLD
>A>	AB			1%	A076075	001	Nov 26, 2002	Mar CRLD
>D>	AB		PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar CRLD
>A>	AB	+		1%	A076479	001	Jun 23, 2004	Mar CRLD

EDOXABAN TOSYLATETABLET;ORAL
SAVAYSADAIICHI SANKYO
EQ 15MG BASE
EQ 30MG BASE
+N206316 001 Jan 08, 2015 Jan NEWA
N206316 002 Jan 08, 2015 Jan NEWA
N206316 003 Jan 08, 2015 Jan NEWAEDROPHONIUM CHLORIDEINJECTABLE; INJECTION
ENLON

>D>	AP		MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar CRLD
>A>		+		10MG/ML	A088873	001	Aug 06, 1985	Mar CRLD
>D>			TENSILON					
>D>	AP	+	VALEANT PHARMS	10MG/ML	N007959	001		Mar DISC
>A>		@		10MG/ML	N007959	001		Mar DISC

<u>INJECTABLE; INJECTION</u>										
TENSILON PRESERVATIVE FREE										
>D>	AP	+	VALEANT PHARMS	10MG/ML		N007959	002		Mar	DISC
>D>	AP	+		10MG/ML		N007959	002		Mar	DISC
>A>		@		10MG/ML		N007959	002		Mar	DISC
<u>ELTROMBOPAG OLAMINE</u>										
TABLET; ORAL										
PROMACTA										
>D>			GLAXOSMITHKLINE	EQ 12.5MG ACID		N022291	004	Oct 20, 2011	Mar	CAHN
>D>				EQ 25MG ACID		N022291	001	Nov 20, 2008	Mar	CAHN
>D>		+		EQ 50MG ACID		N022291	002	Nov 20, 2008	Mar	CAHN
>D>				EQ 75MG ACID		N022291	003	Sep 08, 2009	Mar	CAHN
>D>				EQ 100MG ACID		N022291	005	Nov 16, 2012	Mar	CAHN
>A>			NOVARTIS PHARMS CORP	EQ 12.5MG ACID		N022291	004	Oct 20, 2011	Mar	CAHN
>A>				EQ 25MG ACID		N022291	001	Nov 20, 2008	Mar	CAHN
>A>		+		EQ 50MG ACID		N022291	002	Nov 20, 2008	Mar	CAHN
>A>				EQ 75MG ACID		N022291	003	Sep 08, 2009	Mar	CAHN
>A>				EQ 100MG ACID		N022291	005	Nov 16, 2012	Mar	CAHN
<u>EMPAGLIFLOZIN; LINAGLIPTIN</u>										
TABLET; ORAL										
GLYXAMBI										
			BOEHRINGER INGELHEIM	10MG; 5MG		N206073	001	Jan 30, 2015	Jan	NEWA
		+		25MG; 5MG		N206073	002	Jan 30, 2015	Jan	NEWA
<u>ENALAPRIL MALEATE</u>										
TABLET; ORAL										
ENALAPRIL MALEATE										
>D>		@	SANDOZ INC	2.5MG		A075496	001	Aug 22, 2000	Mar	CMFD
>A>	AB			2.5MG		A075496	001	Aug 22, 2000	Mar	CMFD
>D>		@		5MG		A075496	002	Aug 22, 2000	Mar	CMFD
>A>	AB			5MG		A075496	002	Aug 22, 2000	Mar	CMFD
>D>		@		10MG		A075459	001	Aug 22, 2000	Mar	CMFD
>A>	AB			10MG		A075459	001	Aug 22, 2000	Mar	CMFD
>D>		@		20MG		A075459	002	Aug 22, 2000	Mar	CMFD
>A>	AB			20MG		A075459	002	Aug 22, 2000	Mar	CMFD
<u>ERGOCALCIFEROL</u>										
CAPSULE; ORAL										
VITAMIN D										
AA			BANNER LIFE SCIENCES	50,000 IU		A080704	001		Jan	CAHN
<u>ESMOLOL HYDROCHLORIDE</u>										
INJECTABLE; INJECTION										
ESMOLOL HYDROCHLORIDE										
AP			LUITPOLD	10MG/ML		A201126	001	Feb 20, 2015	Feb	NEWA
<u>ESOMEPRAZOLE MAGNESIUM</u>										
CAPSULE, DELAYED REL PELLETS; ORAL										
ESOMEPRAZOLE MAGNESIUM										
AB			IVAX SUB TEVA PHARMS	EQ 20MG BASE		A078003	001	Jan 26, 2015	Jan	NEWA
AB				EQ 40MG BASE		A078003	002	Jan 26, 2015	Jan	NEWA
NEXIUM										
AB			ASTRAZENECA PHARMS	EQ 20MG BASE		N021153	001	Feb 20, 2001	Jan	CFTG
AB		+		EQ 40MG BASE		N021153	002	Feb 20, 2001	Jan	CFTG
<u>ESTRADIOL</u>										
FILM, EXTENDED RELEASE; TRANSDERMAL										
ALORA										
>A>	BX		ACTAVIS LABS UT INC	0.025MG/24HR		N020655	004	Apr 05, 2002	Mar	CAHN
>A>	BX			0.05MG/24HR		N020655	001	Dec 20, 1996	Mar	CAHN
>A>	BX			0.075MG/24HR		N020655	002	Dec 20, 1996	Mar	CAHN
>A>	BX			0.1MG/24HR		N020655	003	Dec 20, 1996	Mar	CAHN
>D>	BX		WATSON LABS	0.025MG/24HR		N020655	004	Apr 05, 2002	Mar	CAHN
>D>	BX			0.05MG/24HR		N020655	001	Dec 20, 1996	Mar	CAHN
>D>	BX			0.075MG/24HR		N020655	002	Dec 20, 1996	Mar	CAHN
>D>	BX			0.1MG/24HR		N020655	003	Dec 20, 1996	Mar	CAHN
MINIVELLE										
			NOVEN	0.025MG/24HR		N203752	005	Sep 23, 2014	Jan	NEWA

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB	MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015	Jan	NEWA
AB		2MG	A202929	002	Jan 30, 2015	Jan	NEWA
AB		3MG	A202929	003	Jan 30, 2015	Jan	NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

AB	VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Jan	CMFD
AB		400MG	A075095	002	Nov 30, 1999	Jan	CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

ASHLYNA

AB	GLENMARK GENERICS	0.03MG,0.01MG;0.15MG,N/A	A203163	001	Feb 23, 2015	Feb	NEWA	
	LEVONORGESTREL AND ETHINYL ESTRADIOL							
>A>	AB	GLENMARK GENERICS	0.02MG;0.09MG	A202791	001	Apr 09, 2015	Mar	NEWA
>D>	+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	Mar	CTEC
>A>	AB	+	0.02MG;0.09MG	A079218	001	Jun 06, 2011	Mar	CTEC

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ORTHO EVRA

	@ JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Feb	DISC	
	XULANE							
AB	+	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

>A>	@	ACTAVIS LABS UT INC	0.035MG;0.5MG	N017566	001		Mar	CAHN
>D>	@	WATSON LABS	0.035MG;0.5MG	N017566	001		Mar	CAHN
	NORINYL 1+35 21-DAY							
AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	001		Feb	CAHN
	TRI-NORINYL 21-DAY							
	@	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	001	Apr 13, 1984	Feb	CAHN

TABLET;ORAL-28

BREVICON 28-DAY

>A>	AB	ACTAVIS LABS UT INC	0.035MG;0.5MG	N017743	001		Mar	CAHN
>D>	AB	WATSON LABS	0.035MG;0.5MG	N017743	001		Mar	CAHN
	NORINYL 1+35 28-DAY							
AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	002		Feb	CAHN
	TRI-NORINYL 28-DAY							
AB	+	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	002	Apr 13, 1984	Feb	CAHN

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>A>	AB	FAMY CARE LTD	0.035MG;0.4MG	A202086	001	Apr 01, 2015	Mar	NEWA
-----	----	---------------	---------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

FEMHRT

>D>		WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Mar	CTEC
>A>	AB		0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Mar	CTEC
	LARIN 24 FE							
AB		NOVAST LABS LTD	0.02MG;1MG	A202994	001	Feb 18, 2015	Feb	NEWA
	LOESTRIN 24 FE							
	@	WARNER CHILCOTT	0.02MG;1MG	N021871	001	Feb 17, 2006	Jan	DISC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
>D>	+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Mar	CTEC
>A>	AB	+	0.005MG;1MG	A076221	001	Nov 06, 2009	Mar	CTEC
>A>	AB	GLENMARK GENERICS	0.0025MG;0.5MG	A203038	001	Apr 02, 2015	Mar	NEWA
>A>	AB		0.005MG;1MG	A203038	002	Apr 02, 2015	Mar	NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	+	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jan	CRLD

TABLET;ORAL-21

	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
AB	FAMY CARE LTD	0.03MG;1.5MG	A202770	001	Feb 19, 2015	Feb	NEWA

TABLET;ORAL-28

	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
AB	FAMY CARE LTD	0.03MG;1.5MG	A202741	001	Feb 20, 2015	Feb	NEWA

ETHINYL ESTRADIOL; NORGESTIMATETABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

>A>	AB	OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG	A200383	001	Apr 07, 2015	Mar	NEWA
>A>	AB		0.035MG;0.25MG	A200384	001	Apr 07, 2015	Mar	NEWA

ETHINYL ESTRADIOL; NORGESTRELTABLET;ORAL-28

LOW-OGESTREL-28

AB	WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Feb	CMFD
----	-------------	--------------	---------	-----	--------------	-----	------

ETHOSUXIMIDECAPSULE;ORAL

ETHOSUXIMIDE

AB	BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan	CAHN
----	----------------------	-------	---------	-----	--------------	-----	------

FAMOTIDINETABLET;ORAL

PEPCID

AB	VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb	CAHN
AB	+	40MG	N019462	002	Oct 15, 1986	Feb	CAHN

FENTANYLFILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

>A>	AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN
>D>	AB	WATSON LABS	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN

FENTANYL-25

>A>	AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN
>D>	AB	WATSON LABS	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN

FENTANYL-50

>A>	AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN
>D>	AB	WATSON LABS	50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN

FENTANYL-75

>A>	AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN
>D>	AB	WATSON LABS	75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN

FENTANYL CITRATEFILM;BUCCAL

ONSOLIS

>A>	@	BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar	CAHN
>A>	@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar	CAHN
>A>	@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar	CAHN
>A>	@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar	CAHN
>A>	@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar	CAHN
>D>	@	MEDA PHARMS	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar	CAHN
>D>	@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar	CAHN
>D>	@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar	CAHN
>D>	@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar	CAHN
>D>	@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar	CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb	CAHN
----	---	--------------------	-------------------	---------	-----	--------------	-----	------

FERRIC CITRATETABLET;ORAL

AURYXIA

	+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan	CTNA
--	---	-----------------	---------------	---------	-----	--------------	-----	------

FERRIC PYROPHOSPHATE CITRATESOLUTION;IV (INFUSION)
TRIFERIC

+ ROCKWELL MEDICAL INC 27.2MG IRON/5ML (5.44MG IRON/ML) N206317 001 Jan 23, 2015 Jan NEWA

FLUDEOXYGLUCOSE F-18INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F 18

UNIV NORTH DAKOTA 4-500mCi/ML A203994 001 Feb 04, 2015 Jan NEWA

FLUDEOXYGLUCOSE F18

>A> PRECISION NUCLEAR 20-500mCi/ML A204546 001 Apr 07, 2015 Mar NEWA

FLUOROURACILCREAM;TOPICAL
CARAC

+ VALEANT PHARMS NORTH 0.5% N020985 001 Oct 27, 2000 Feb CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

>D> AB2 ANI PHARMS INC EQ 10MG BASE A076287 001 May 20, 2008 Mar DISC

>A> @ EQ 10MG BASE A076287 001 May 20, 2008 Mar DISC

>D> AB2 EQ 20MG BASE A076287 002 May 20, 2008 Mar DISC

>A> @ EQ 20MG BASE A076287 002 May 20, 2008 Mar DISC

>D> AB2 MYLAN EQ 20MG BASE A078045 002 Nov 17, 2008 Mar CTEC

>A> + EQ 20MG BASE A078045 002 Nov 17, 2008 Mar CRLD

>A> EQ 20MG BASE A078045 002 Nov 17, 2008 Mar CTEC

>D> AB2 SANDOZ EQ 10MG BASE A077469 001 Nov 17, 2008 Mar DISC

>A> @ EQ 10MG BASE A077469 001 Nov 17, 2008 Mar DISC

>D> AB2 EQ 20MG BASE A077469 002 Nov 17, 2008 Mar DISC

>A> @ EQ 20MG BASE A077469 002 Nov 17, 2008 Mar DISC

>A> AB1 SCIEGEN PHARMS INC EQ 10MG BASE A204597 001 Mar 16, 2015 Mar NEWA

>A> AB1 EQ 20MG BASE A204597 002 Mar 16, 2015 Mar NEWA

>A> AB EQ 40MG BASE A204597 003 Mar 16, 2015 Mar NEWA

>D> SARAFEM

>D> AB2 ELI LILLY AND CO EQ 10MG BASE N018936 007 Jul 06, 2000 Mar DISC

>A> @ EQ 10MG BASE N018936 007 Jul 06, 2000 Mar DISC

>D> AB2 + EQ 20MG BASE N018936 008 Jul 06, 2000 Mar DISC

>A> @ EQ 20MG BASE N018936 008 Jul 06, 2000 Mar DISC

FLURANDRENOLIDETAPE;TOPICAL
CORDRAN

>A> + ACTAVIS LABS UT INC 0.004MG/SQ CM N016455 001 Mar CAHN

>D> + WATSON LABS INC 0.004MG/SQ CM N016455 001 Mar CAHN

FUROSEMIDEINJECTABLE;INJECTION
FUROSEMIDE

>D> @ ASTRAZENECA 10MG/ML A070095 001 Sep 09, 1985 Mar CAHN

>D> @ 10MG/ML A070096 001 Sep 09, 1985 Mar CAHN

>A> @ IGI LABS INC 10MG/ML A070095 001 Sep 09, 1985 Mar CAHN

>A> @ 10MG/ML A070096 001 Sep 09, 1985 Mar CAHN

GADOVERSETAMIDEINJECTABLE;INJECTION
OPTIMARK

+ LIEBEL-FLARSHEIM 16.545GM/50ML (330.9MG/ML) N020975 001 Dec 08, 1999 Feb CAHN

+ 1654.5MG/5ML (330.9MG/ML) N020937 001 Dec 08, 1999 Feb CAHN

+ 3309MG/10ML (330.9MG/ML) N020937 002 Dec 08, 1999 Feb CAHN

+ 4963.5MG/15ML (330.9MG/ML) N020937 003 Dec 08, 1999 Feb CAHN

+ 6618MG/20ML (330.9MG/ML) N020937 004 Dec 08, 1999 Feb CAHN

OPTIMARK IN PLASTIC CONTAINER

+ LIEBEL-FLARSHEIM 3309MG/10ML (330.9MG/ML) N020976 002 Dec 08, 1999 Feb CAHN

+ 4963.5MG/15ML (330.9MG/ML) N020976 003 Dec 08, 1999 Feb CAHN

+ 6618MG/20ML (330.9MG/ML) N020976 004 Dec 08, 1999 Feb CAHN

+ 9927MG/30ML (330.9MG/ML) N020976 001 Dec 08, 1999 Feb CAHN

GLATIRAMER ACETATEINJECTABLE;SUBCUTANEOUS
COPAXONE

>D>	+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar	CFTG
>A>	AP	+	20MG/ML	N020622	002	Feb 12, 2002	Mar	CFTG
>A>		GLATOPA						
>A>	AP	SANDOZ, INC	20MG/ML	A090218	001	Apr 16, 2015	Mar	NEWA

GRANISETRON HYDROCHLORIDEINJECTABLE;INJECTION
GRANISETRON HYDROCHLORIDE

AP		BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan	CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan	CAHN
AP		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP		BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan	CAHN

HYDRALAZINE HYDROCHLORIDEINJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009	Feb	CRLD
AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb	CRLD

HYDROCHLOROTHIAZIDECAPSULE;ORAL
MICROZIDE

AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Feb	CAHN
----	---	---------------------	--------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; LISINAPRILTABLET;ORAL
ZESTORETIC

AB		ALVOGEN IPCO SARL	12.5MG;10MG	N019888	003	Nov 18, 1993	Feb	CAHN
AB	+		12.5MG;20MG	N019888	001	Sep 20, 1990	Feb	CAHN
AB	+		25MG;20MG	N019888	002	Jul 20, 1989	Feb	CAHN

HYDROCODONE BITARTRATETABLET, EXTENDED RELEASE;ORAL
HYSINGLA

>D>		PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar	CRLD
>A>		+	20MG	N206627	001	Nov 20, 2014	Mar	CRLD

HYDROCORTISONECREAM;TOPICAL
HYDROCORTISONE

>D>	AT	LYNE	2.5%	A040879	001	Aug 20, 2010	Mar	CAHN
>A>	AT	RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar	CAHN

TABLET;ORAL
HYDROCORTISONE

AB		HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb	NEWA
AB			10MG	A083365	003	Feb 23, 2015	Feb	NEWA
AB			20MG	A083365	001		Feb	CMFD

HYDROMORPHONE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
HYDROMORPHONE HYDROCHLORIDE

>A>	AB	PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar	NEWA
>A>	AB		12MG	A204278	002	Apr 06, 2015	Mar	NEWA
>A>	AB		16MG	A204278	003	Apr 06, 2015	Mar	NEWA

HYDROXYPROGESTERONE CAPROATEINJECTABLE;INJECTION
HYDROXYPROGESTERONE CAPROATE

>A>		@ ACTAVIS LABS UT INC	125MG/ML	N017439	001		Mar	CAHN
>A>		@	250MG/ML	N017439	002		Mar	CAHN
>D>		@ WATSON LABS	125MG/ML	N017439	001		Mar	CAHN
>D>		@	250MG/ML	N017439	002		Mar	CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>D>	AB	EMCURE PHARMS USA	10MG	A204279	001	Aug 20, 2014	Mar	CAHN
>D>	AB		25MG	A204279	002	Aug 20, 2014	Mar	CAHN
>D>	AB		50MG	A204279	003	Aug 20, 2014	Mar	CAHN
>A>	AB	HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar	CAHN
>A>	AB		25MG	A204279	002	Aug 20, 2014	Mar	CAHN
>A>	AB		50MG	A204279	003	Aug 20, 2014	Mar	CAHN
>D>		@ MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar	CMFD
>A>	AB		10MG	A040600	001	Dec 28, 2004	Mar	CMFD
>D>		@	25MG	A040602	001	Dec 28, 2004	Mar	CMFD
>A>	AB		25MG	A040602	001	Dec 28, 2004	Mar	CMFD
>D>		@	50MG	A040604	001	Dec 28, 2004	Mar	CMFD
>A>	AB		50MG	A040604	001	Dec 28, 2004	Mar	CMFD

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

>D>	AB	EMCURE PHARMS USA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar	CAHN
>D>	AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar	CAHN
>A>	AB	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar	CAHN
>A>	AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar	CAHN

LLOPERIDONE

TABLET; ORAL

FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jan	CAHN
		2MG	N022192	002	May 06, 2009	Jan	CAHN
		4MG	N022192	003	May 06, 2009	Jan	CAHN
		6MG	N022192	004	May 06, 2009	Jan	CAHN
		8MG	N022192	005	May 06, 2009	Jan	CAHN
		10MG	N022192	006	May 06, 2009	Jan	CAHN
		12MG	N022192	007	May 06, 2009	Jan	CAHN

INSULIN GLARGINE

SOLUTION; SUBCUTANEOUS

TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300UNITS/ML (300UNITS/ML)	N206538	001	Feb 25, 2015	Feb	NEWA
---	--------------------	---------------------------	---------	-----	--------------	-----	------

INSULIN GLARGINE RECOMBINANT

SOLUTION; SUBCUTANEOUS

TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300UNITS/ML (300UNITS/ML)	N206538	001	Feb 25, 2015	Feb	NEWA
---	--------------------	---------------------------	---------	-----	--------------	-----	------

IOHEXOL

>A>		FOR SOLUTION; ORAL						
>A>		ORALTAG						
>A>		INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015	Mar	NEWA

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-250

@	FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997	Jan	DISC
	IOPAMIDOL-300						
@	FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997	Jan	DISC
	IOPAMIDOL-370						
@	FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997	Jan	DISC
	ISOVUE-200						
+	BRACCO	41%	N018735	006	Jul 07, 1987	Feb	CTEC
	ISOVUE-250						
+	BRACCO	51%	N018735	007	Jul 06, 1992	Feb	CTEC
+		51%	N020327	002	Oct 12, 1994	Feb	CTEC
	ISOVUE-300						
+	BRACCO	61%	N020327	003	Oct 12, 1994	Feb	CTEC
	ISOVUE-370						
+	BRACCO	76%	N020327	004	Oct 12, 1994	Feb	CTEC

IOTHALAMATE MEGLUMINEINJECTABLE; INJECTION
CONRAY

+	LIEBEL-FLARSHEIM	60%	N013295	001		Feb	CAHN
	CONRAY 30						
+	LIEBEL-FLARSHEIM	30%	N016983	001		Feb	CAHN
	CONRAY 43						
+	LIEBEL-FLARSHEIM	43%	N013295	002		Feb	CAHN
	SOLUTION; INTRAVESICAL						
	CYSTO-CONRAY II						
	LIEBEL-FLARSHEIM	17.2%	N017057	002		Feb	CAHN

IOVERSOLINJECTABLE; INJECTION
OPTIRAY 160

@	LIEBEL-FLARSHEIM	34%	N019710	003	Dec 30, 1988	Feb	CAHN
	OPTIRAY 240						
+	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988	Feb	CAHN
	@	51%	N020923	001	May 28, 1998	Feb	CAHN
	OPTIRAY 300						
+	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992	Feb	CAHN
+		64%	N020923	004	May 13, 1999	Feb	CAHN
	OPTIRAY 320						
+	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988	Feb	CAHN
	@	68%	N020923	002	May 29, 1998	Feb	CAHN
	OPTIRAY 350						
+	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992	Feb	CAHN
+		74%	N020923	003	May 28, 1998	Feb	CAHN

IRBESARTANTABLET; ORAL
IRBESARTAN

AB	JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015	Feb	NEWA
AB		150MG	A203534	002	Feb 23, 2015	Feb	NEWA
AB		300MG	A203534	003	Feb 23, 2015	Feb	NEWA

IRON DEXTRANINJECTABLE; INJECTION
INFED

>A>	BP	+	ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441	001		Mar	CAHN
>D>	BP	+	WATSON LABS (UTAH)	EQ 50MG IRON/ML	N017441	001		Mar	CAHN

>A> ISAVUCONAZONIUM SULFATE

>A>			CAPSULE; ORAL						
>A>			CRESEMBA						
>A>		+	ASTELLAS	186MG	N207500	001	Mar 06, 2015	Mar	NEWA
>A>			POWDER; IV (INFUSION)						
>A>			CRESEMBA						
>A>		+	ASTELLAS	372MG	N207501	001	Mar 06, 2015	Mar	NEWA

ISOSORBIDE DINITRATETABLET; ORAL
ISORDIL

AB	VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb	CAHN
	@	10MG	N012093	002	Jul 29, 1988	Feb	CAHN
	@	20MG	N012093	006	Jul 29, 1988	Feb	CAHN
	@	30MG	N012093	005	Jul 29, 1988	Feb	CAHN
	+	40MG	N012093	001	Jul 29, 1988	Feb	CAHN

ISOTRETINOIN

CAPSULE; ORAL

	ABSORICA								
	RANBAXY	25MG	N021951	005	Aug 15, 2014	Feb	NEWA		
		35MG	N021951	006	Aug 15, 2014	Feb	NEWA		
	ZENATANE								
AB	DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb	NEWA		

ISRADIPINECAPSULE;ORAL
ISRADIPINE

>A>	AB	ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar	CAHN
>A>	AB		5MG	A077169	002	Apr 24, 2006	Mar	CAHN
>D>	AB	MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	Mar	CAHN
>D>	AB		5MG	A077169	002	Apr 24, 2006	Mar	CAHN

IVACAFTOR>A> GRANULE;ORAL
>A> KALYDECO

>A>		VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015	Mar	NEWA
>A>		+	75MG/PACKET	N207925	002	Mar 17, 2015	Mar	NEWA

KETOROLAC TROMETHAMINESPRAY, METERED;NASAL
SPRIX

+		EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010	Jan	CAHN
---	--	---------------	---------------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDESOLUTION;IRRIGATION
OMIDRIA

+		OMEROS	EQ 4.24MG BASE/ML;EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	Feb	CPOF
---	--	--------	--	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB		MUTUAL PHARM	100MG	A075215	001	Jul 29, 1999	Jan	CMFD
AB			200MG	A075215	002	Jul 29, 1999	Jan	CMFD
AB			300MG	A075215	003	Jul 29, 1999	Jan	CMFD

LACTULOSESOLUTION;ORAL, RECTAL
LACTULOSE

>A>	AA	BIO-PHARM INC	10GM/15ML	A203762	001	Mar 27, 2015	Mar	NEWA
-----	----	---------------	-----------	---------	-----	--------------	-----	------

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET;ORAL

DUTREBIS

+		MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015	Feb	NEWA
---	--	-------------------	---------------------	---------	-----	--------------	-----	------

LAPATINIB DITOSYLATE

TABLET;ORAL

TYKERB

>A>		+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar	CAHN
>D>		+	SMITHKLINE BEECHAM	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar	CAHN

LENVATINIB MESYLATE

CAPSULE;ORAL

LENVIMA

		EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015	Feb	NEWA
		+	EQ 10MG BASE	N206947	002	Feb 13, 2015	Feb	NEWA

LEVETIRACETAM

TABLET, EXTENDED RELEASE;ORAL

ELEPSIA XR

>A>			SPARC	1GM	N204417	001	Mar 02, 2015	Mar	NEWA
>A>				1.5GM	N204417	002	Mar 02, 2015	Mar	NEWA
			LEVETIRACETAM						
			APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb	NEWA
----	--	------------	-----	---------	-----	--------------	-----	------

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

>D>		SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar	CRLD
			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb	NEWA
		SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb	NEWA
>A>	+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar	CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

LILETTA

MEDICINES360

52MG

N206229 001 Feb 26, 2015 Feb NEWA

LIDOCAINE

PATCH; TOPICAL

LIDOCAINE

>A>	AB	ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar	CAHN
>D>	AB	WATSON LABS INC	5%	A200675	001	Aug 23, 2012	Mar	CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

>A>		@ EUROHLTH INTL SARL	1%	A080407	001		Mar	CAHN
>A>		@	2%	A080407	002		Mar	CAHN
>D>		@ HIKMA MAPLE	1%	A080407	001		Mar	CAHN
>D>		@	2%	A080407	002		Mar	CAHN
		LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
		@ EUROHLTH INTL SARL	1%	A084625	001		Feb	CAHN
		@	2%	A084625	002		Feb	CAHN
		JELLY; TOPICAL						
		ANESTACON						
		@ BANNER LIFE SCIENCES	2%	A080429	001		Jan	CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB	+	ACTAVIS LABS UT INC	2.5%; 2.5%	N019941	001	Dec 30, 1992	Feb	CAHN
----	---	---------------------	------------	---------	-----	--------------	-----	------

LINACLOTIDE

CAPSULE; ORAL

LINZESS

>D>		FOREST LABS INC	145MCG	N202811	001	Aug 30, 2012	Mar	CAHN
>D>	+		290MCG	N202811	002	Aug 30, 2012	Mar	CAHN
>A>		FOREST LABS LLC	145MCG	N202811	001	Aug 30, 2012	Mar	CAHN
>A>	+		290MCG	N202811	002	Aug 30, 2012	Mar	CAHN

LISINAPRIL

TABLET; ORAL

ZESTRIL

AB		ALVOGEN IPCO SARL	2.5MG	N019777	005	Apr 29, 1993	Feb	CAHN
AB			5MG	N019777	001	May 19, 1988	Feb	CAHN
AB			10MG	N019777	002	May 19, 1988	Feb	CAHN
AB			20MG	N019777	003	May 19, 1988	Feb	CAHN
AB			30MG	N019777	006	Jan 20, 1999	Feb	CAHN
AB	+		40MG	N019777	004	May 19, 1988	Feb	CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

@ HIKMA INTL PHARMS

450MG

A076490 001 Jun 17, 2003 Feb DISC

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

CORDEN PHARMA

5MG

N017588 004 Dec 19, 2014 Jan NEWA

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	WATSON LABS	25MG	A091129	001	Oct 06, 2010	Feb	CMFD
AB		50MG	A091129	002	Oct 06, 2010	Feb	CMFD
AB		100MG	A091129	003	Oct 06, 2010	Feb	CMFD

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

>A>	@ ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001		Mar	CAHN
>D>	@ WATSON LABS	EQ 25MG BASE/ML	N017658	001		Mar	CAHN

INJECTABLE; INJECTION

LOXITANE IM

>A>	@ ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001		Mar	CAHN
>D>	@ WATSON LABS	EQ 50MG BASE/ML	N018039	001		Mar	CAHN

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

>A>	@ ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001		Mar	CAHN
>A>	@	EQ 10MG BASE	N017525	002		Mar	CAHN
>A>	@	EQ 25MG BASE	N017525	003		Mar	CAHN
>A>	@	EQ 50MG BASE	N017525	004		Mar	CAHN
>D>	@ WATSON LABS	EQ 5MG BASE	N017525	001		Mar	CAHN
>D>	@	EQ 10MG BASE	N017525	002		Mar	CAHN
>D>	@	EQ 25MG BASE	N017525	003		Mar	CAHN
>D>	@	EQ 50MG BASE	N017525	004		Mar	CAHN

TABLET; ORAL

LOXITANE

>A>	@ ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Mar	CAHN
>A>	@	EQ 25MG BASE	N017525	007		Mar	CAHN
>A>	@	EQ 50MG BASE	N017525	008		Mar	CAHN
>D>	@ WATSON LABS	EQ 10MG BASE	N017525	006		Mar	CAHN
>D>	@	EQ 25MG BASE	N017525	007		Mar	CAHN
>D>	@	EQ 50MG BASE	N017525	008		Mar	CAHN

>D> MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

>D> INJECTABLE; INJECTION

>D> PLASMA-LYTE 56 IN PLASTIC CONTAINER

>D>	BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984	Mar	DISC
>A>	@	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984	Mar	DISC

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

>D>	@ ASTRAZENECA	12.5GM/50ML	A089239	001	May 06, 1987	Mar	CAHN
>D>	@	12.5GM/50ML	A089240	001	May 06, 1987	Mar	CAHN
>A>	@ IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar	CAHN
>A>	@	12.5GM/50ML	A089240	001	May 06, 1987	Mar	CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMENDA XR

>D>	FOREST LABS	7MG	N022525	001	Jun 21, 2010	Mar	CAHN
>D>		14MG	N022525	002	Jun 21, 2010	Mar	CAHN
>D>		21MG	N022525	003	Jun 21, 2010	Mar	CAHN
>D>	+	28MG	N022525	004	Jun 21, 2010	Mar	CAHN
>A>	FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar	CAHN
>A>		14MG	N022525	002	Jun 21, 2010	Mar	CAHN
>A>		21MG	N022525	003	Jun 21, 2010	Mar	CAHN
>A>	+	28MG	N022525	004	Jun 21, 2010	Mar	CAHN

SOLUTION; ORAL

NAMENDA

>D>	+ FOREST LABS	2MG/ML	N021627	001	Apr 18, 2005	Mar	CAHN
>A>	+ FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Mar	CAHN

TABLET; ORAL

MEMANTINE

>D>	@ SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar	CMFD
>A>	AB	5MG	A090058	001	May 05, 2010	Mar	CMFD
>D>	@	10MG	A090058	002	May 05, 2010	Mar	CMFD

TABLET; ORAL
MEMANTINE

>A>	AB		10MG	A090058	002	May 05, 2010	Mar	CMFD
		MEMANTINE HYDROCHLORIDE						
>A>	AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar	NEWA
>A>	AB		10MG	A090041	002	Apr 10, 2015	Mar	NEWA
>A>	AB	LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar	NEWA
>A>	AB		10MG	A090051	002	Apr 10, 2015	Mar	NEWA
>D>	AB	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Mar	DISC
>A>		@	5MG	A079225	001	Jan 30, 2015	Mar	DISC
	AB		5MG	A079225	001	Jan 30, 2015	Jan	NEWA
>D>	AB		10MG	A079225	002	Jan 30, 2015	Mar	DISC
>A>		@	10MG	A079225	002	Jan 30, 2015	Mar	DISC
	AB		10MG	A079225	002	Jan 30, 2015	Jan	NEWA
		NAMENDA						
>D>	AB	FOREST LABS	5MG	N021487	001	Oct 16, 2003	Mar	CAHN
>D>	AB	+	10MG	N021487	002	Oct 16, 2003	Mar	CAHN
>A>	AB	FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar	CAHN
>A>	AB	+	10MG	N021487	002	Oct 16, 2003	Mar	CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

>D>		@ ASTRAZENECA	50MG/ML	A089782	001	Mar 31, 1989	Mar	CAHN
>D>		@	50MG/ML	A089783	001	Mar 31, 1989	Mar	CAHN
>D>		@	50MG/ML	A089784	001	Mar 31, 1989	Mar	CAHN
>D>		@	75MG/ML	A089785	001	Mar 31, 1989	Mar	CAHN
>D>		@	100MG/ML	A089786	001	Mar 31, 1989	Mar	CAHN
>D>		@	100MG/ML	A089787	001	Mar 31, 1989	Mar	CAHN
>D>		@	100MG/ML	A089788	001	Mar 31, 1989	Mar	CAHN
AP		EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb	CAHN
AP			50MG/ML	A080445	002		Feb	CAHN
AP			75MG/ML	A080445	003		Feb	CAHN
AP			100MG/ML	A080445	004		Feb	CAHN
>A>		@ IGI LABS INC	50MG/ML	A089782	001	Mar 31, 1989	Mar	CAHN
>A>		@	50MG/ML	A089783	001	Mar 31, 1989	Mar	CAHN
>A>		@	50MG/ML	A089784	001	Mar 31, 1989	Mar	CAHN
>A>		@	75MG/ML	A089785	001	Mar 31, 1989	Mar	CAHN
>A>		@	100MG/ML	A089786	001	Mar 31, 1989	Mar	CAHN
>A>		@	100MG/ML	A089787	001	Mar 31, 1989	Mar	CAHN
>A>		@	100MG/ML	A089788	001	Mar 31, 1989	Mar	CAHN

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

>A>		@ ACTAVIS LABS UT INC	0.1MG;2MG	N013625	004		Mar	CAHN
>D>		@ WATSON LABS	0.1MG;2MG	N013625	004		Mar	CAHN

TABLET; ORAL-21

NORINYL 1+50 21-DAY

>A>		@ ACTAVIS LABS UT INC	0.05MG;1MG	N013625	002		Mar	CAHN
>D>		@ WATSON LABS	0.05MG;1MG	N013625	002		Mar	CAHN

TABLET; ORAL-28

NORINYL 1+50 28-DAY

>A>		+ ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001		Mar	CAHN
>D>		+ WATSON LABS	0.05MG;1MG	N016659	001		Mar	CAHN

METAXALONE

TABLET; ORAL

METAXALONE

COREPHARMA

400MG

A040486 001 Feb 27, 2015 Feb NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

>D>	AB	EMCURE PHARMS USA	5MG	A040734	001	Dec 14, 2007	Mar	CAHN
>D>	AB		10MG	A040734	002	Dec 14, 2007	Mar	CAHN
>A>	AB	HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar	CAHN
>A>	AB		10MG	A040734	002	Dec 14, 2007	Mar	CAHN

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
RITALIN LA

AB1	NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb	CRLD
	+	60MG	N021284	005	Oct 27, 2014	Feb	CRLD

TABLET, CHEWABLE;ORAL

METHYLIN

AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb	CFTG
AB		5MG	N021475	002	Apr 15, 2003	Feb	CFTG
AB	+	10MG	N021475	003	Apr 15, 2003	Feb	CFTG

METHYLPHENIDATE HYDROCHLORIDE

AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb	NEWA
AB		5MG	A204115	002	Feb 25, 2015	Feb	NEWA
AB		10MG	A204115	003	Feb 25, 2015	Feb	NEWA

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

>A>	MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar	NEWA
>A>		75MG	A076704	005	Mar 18, 2015	Mar	NEWA

METRONIDAZOLE

CREAM;TOPICAL

NORITATE

+ VALEANT PHARMS NORTH 1%

N020743 001 Sep 26, 1997 Feb CAHN

GEL;VAGINAL

METRONIDAZOLE

+ ACTAVIS LABS UT INC 1.3%

N205223 001 Mar 24, 2014 Feb CAHN

NUVESSA

+ ACTAVIS LABS UT INC 1.3%

N205223 001 Mar 24, 2014 Feb CTNA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>D>	AP	WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar	DISC
>A>		@	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar	DISC
>D>	AP		EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar	DISC
>A>		@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar	DISC
>D>	AP		EQ 5MG BASE/ML	A078141	002	May 30, 2008	Mar	DISC
>A>		@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Mar	DISC
>D>	AP		EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Mar	DISC
>A>		@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Mar	DISC

MIGLITOL

TABLET;ORAL

GLYSET

>D>	AA	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Mar	CTEC
>A>	AB		25MG	N020682	001	Dec 18, 1996	Mar	CTEC
	AA		25MG	N020682	001	Dec 18, 1996	Feb	CFTG
>D>	AA		50MG	N020682	002	Dec 18, 1996	Mar	CTEC
>A>	AB		50MG	N020682	002	Dec 18, 1996	Mar	CTEC
	AA		50MG	N020682	002	Dec 18, 1996	Feb	CFTG
>D>	AA	+	100MG	N020682	003	Dec 18, 1996	Mar	CTEC
>A>	AB	+	100MG	N020682	003	Dec 18, 1996	Mar	CTEC
	AA	+	100MG	N020682	003	Dec 18, 1996	Feb	CFTG

MIGLITOL

>D>	AA	ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015	Mar	CTEC
>A>	AB		25MG	A203965	001	Feb 24, 2015	Mar	CTEC
	AA		25MG	A203965	001	Feb 24, 2015	Feb	NEWA
>D>	AA		50MG	A203965	002	Feb 24, 2015	Mar	CTEC
>A>	AB		50MG	A203965	002	Feb 24, 2015	Mar	CTEC
	AA		50MG	A203965	002	Feb 24, 2015	Feb	NEWA
>D>	AA		100MG	A203965	003	Feb 24, 2015	Mar	CTEC
>A>	AB		100MG	A203965	003	Feb 24, 2015	Mar	CTEC
	AA		100MG	A203965	003	Feb 24, 2015	Feb	NEWA

MILRINONE LACTATEINJECTABLE; INJECTION
MILRINONE LACTATE

AP	BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan	CRLD
AP	+ HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03, 2010	Jan	CRLD

MIVACURIUM CHLORIDESOLUTION; INTRAVENOUS
MIVACRON

ABBVIE

EQ 10MG BASE/5ML (EQ 2MG BASE/ML)

N020098 004 Jan 22, 1992 Jan NEWA

+

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

N020098 005 Jan 22, 1992 Jan NEWA

>A> MOLINDONE HYDROCHLORIDE

>A> TABLET; ORAL

>A> MOLINDONE HYDROCHLORIDE

>A> COREPHARMA

5MG

A090453 001 Mar 20, 2015 Mar NEWA

>A> 10MG

A090453 002 Mar 20, 2015 Mar NEWA

>A> + 25MG

A090453 003 Mar 20, 2015 Mar NEWA

MONTELUKAST SODIUM

TABLET; ORAL

MONTELUKAST SODIUM

>A> AB KREMERS URBAN PHARMS EQ 10MG BASE

A201522 001 Aug 03, 2012 Mar CAHN

>D> AB KUDCO IRELAND EQ 10MG BASE

A201522 001 Aug 03, 2012 Mar CAHN

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB JUBILANT GENERICS EQ 4MG BASE

A203795 001 Feb 27, 2015 Feb NEWA

AB EQ 5MG BASE

A203795 002 Feb 27, 2015 Feb NEWA

>A> AB KREMERS URBAN PHARMS EQ 4MG BASE

A200405 001 Aug 03, 2012 Mar CAHN

>A> AB EQ 5MG BASE

A200405 002 Aug 03, 2012 Mar CAHN

>D> AB KUDCO IRELAND EQ 4MG BASE

A200405 001 Aug 03, 2012 Mar CAHN

>D> AB EQ 5MG BASE

A200405 002 Aug 03, 2012 Mar CAHN

AB MACLEODS PHARMS LTD EQ 4MG BASE

A203582 001 Mar 12, 2015 Feb NEWA

AB EQ 5MG BASE

A203582 002 Mar 12, 2015 Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

>A> AB1 + ACTAVIS LABS UT INC 10MG N020616 008 Apr 20, 2007 Mar CAHN

>A> AB1 20MG N020616 001 Jul 03, 1996 Mar CAHN

>A> AB1 30MG N020616 004 Mar 09, 2001 Mar CAHN

>A> 40MG N020616 009 Jul 09, 2012 Mar CAHN

>A> AB1 50MG N020616 002 Jul 03, 1996 Mar CAHN

>A> AB1 60MG N020616 005 Mar 09, 2001 Mar CAHN

>A> 70MG N020616 010 Jul 09, 2012 Mar CAHN

>A> AB1 80MG N020616 006 Oct 27, 2006 Mar CAHN

>A> AB1 + 100MG N020616 003 Jul 03, 1996 Mar CAHN

>A> 130MG N020616 011 Jul 09, 2012 Mar CAHN

>A> 150MG N020616 012 Jul 09, 2012 Mar CAHN

>A> AB1 + 200MG N020616 007 Feb 27, 2007 Mar CAHN

>D> AB1 + WATSON LABS INC 10MG N020616 008 Apr 20, 2007 Mar CAHN

>D> AB1 20MG N020616 001 Jul 03, 1996 Mar CAHN

>D> AB1 30MG N020616 004 Mar 09, 2001 Mar CAHN

>D> 40MG N020616 009 Jul 09, 2012 Mar CAHN

>D> AB1 50MG N020616 002 Jul 03, 1996 Mar CAHN

>D> AB1 60MG N020616 005 Mar 09, 2001 Mar CAHN

>D> 70MG N020616 010 Jul 09, 2012 Mar CAHN

>D> AB1 80MG N020616 006 Oct 27, 2006 Mar CAHN

>D> AB1 + 100MG N020616 003 Jul 03, 1996 Mar CAHN

>D> 130MG N020616 011 Jul 09, 2012 Mar CAHN

>D> 150MG N020616 012 Jul 09, 2012 Mar CAHN

>D> AB1 + 200MG N020616 007 Feb 27, 2007 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

>A> AB ACTAVIS ELIZABETH 15MG A203849 001 Apr 06, 2015 Mar NEWA

>A> AB 30MG A203849 002 Apr 06, 2015 Mar NEWA

>A> AB 60MG A203849 003 Apr 06, 2015 Mar NEWA

>A> AB 100MG A203849 004 Apr 06, 2015 Mar NEWA

>A> AB 200MG A203849 005 Apr 06, 2015 Mar NEWA

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT WATSON LABS INC EQ 0.5% BASE A202525 001 Mar 06, 2015 Feb NEWA

NALBUPHINE HYDROCHLORIDEINJECTABLE; INJECTION
NALBUPHINE HYDROCHLORIDE

>D>	@	ASTRAZENECA	10MG/ML	A072070	001	Apr 10, 1989	Mar	CAHN
>D>	@		10MG/ML	A072071	001	Apr 10, 1989	Mar	CAHN
>D>	@		10MG/ML	A072072	001	Apr 10, 1989	Mar	CAHN
>D>	@		20MG/ML	A072073	001	Apr 10, 1989	Mar	CAHN
>D>	@		20MG/ML	A072074	001	Apr 10, 1989	Mar	CAHN
>D>	@		20MG/ML	A072075	001	Apr 10, 1989	Mar	CAHN
>A>	@	IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar	CAHN
>A>	@		10MG/ML	A072071	001	Apr 10, 1989	Mar	CAHN
>A>	@		10MG/ML	A072072	001	Apr 10, 1989	Mar	CAHN
>A>	@		20MG/ML	A072073	001	Apr 10, 1989	Mar	CAHN
>A>	@		20MG/ML	A072074	001	Apr 10, 1989	Mar	CAHN
>A>	@		20MG/ML	A072075	001	Apr 10, 1989	Mar	CAHN

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION
NALOXONE

>A>	@	EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar	CAHN
>D>	@	HIKMA MAPLE	0.4MG/ML	A070299	001	Sep 24, 1986	Mar	CAHN
NALOXONE HYDROCHLORIDE								
>D>	@	ASTRAZENECA	0.02MG/ML	A072082	001	Apr 11, 1989	Mar	CAHN
>D>	@		0.02MG/ML	A072083	001	Apr 11, 1989	Mar	CAHN
>D>	@		0.02MG/ML	A072084	001	Apr 11, 1989	Mar	CAHN
>D>	@		0.02MG/ML	A072085	001	Apr 11, 1989	Mar	CAHN
>D>	@		0.4MG/ML	A072086	001	Apr 11, 1989	Mar	CAHN
>D>	@		0.4MG/ML	A072087	001	Apr 11, 1989	Mar	CAHN
>D>	@		0.4MG/ML	A072088	001	Apr 11, 1989	Mar	CAHN
>D>	@		0.4MG/ML	A072089	001	Apr 11, 1989	Mar	CAHN
>D>	@		0.4MG/ML	A072090	001	Apr 11, 1989	Mar	CAHN
>D>	@		1MG/ML	A072091	001	Apr 11, 1989	Mar	CAHN
>D>	@		1MG/ML	A072092	001	Apr 11, 1989	Mar	CAHN
>D>	@		1MG/ML	A072093	001	Apr 11, 1989	Mar	CAHN
>A>	@	IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar	CAHN
>A>	@		0.02MG/ML	A072083	001	Apr 11, 1989	Mar	CAHN
>A>	@		0.02MG/ML	A072084	001	Apr 11, 1989	Mar	CAHN
>A>	@		0.02MG/ML	A072085	001	Apr 11, 1989	Mar	CAHN
>A>	@		0.4MG/ML	A072086	001	Apr 11, 1989	Mar	CAHN
>A>	@		0.4MG/ML	A072087	001	Apr 11, 1989	Mar	CAHN
>A>	@		0.4MG/ML	A072088	001	Apr 11, 1989	Mar	CAHN
>A>	@		0.4MG/ML	A072089	001	Apr 11, 1989	Mar	CAHN
>A>	@		0.4MG/ML	A072090	001	Apr 11, 1989	Mar	CAHN
>A>	@		1MG/ML	A072091	001	Apr 11, 1989	Mar	CAHN
>A>	@		1MG/ML	A072092	001	Apr 11, 1989	Mar	CAHN
>A>	@		1MG/ML	A072093	001	Apr 11, 1989	Mar	CAHN

NEBIVOLOL HYDROCHLORIDETABLET; ORAL
BYSTOLIC

>D>		FOREST LABS	EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Mar	CFTG
>A>	AB		EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Mar	CFTG
>D>			EQ 5MG BASE	N021742	003	Dec 17, 2007	Mar	CFTG
>A>	AB		EQ 5MG BASE	N021742	003	Dec 17, 2007	Mar	CFTG
>D>			EQ 10MG BASE	N021742	004	Dec 17, 2007	Mar	CFTG
>A>	AB		EQ 10MG BASE	N021742	004	Dec 17, 2007	Mar	CFTG
>D>	+		EQ 20MG BASE	N021742	005	Oct 08, 2008	Mar	CFTG
>A>	AB	+	EQ 20MG BASE	N021742	005	Oct 08, 2008	Mar	CFTG
NEBIVOLOL HYDROCHLORIDE								
>A>	AB	AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Mar	NEWA
>A>	AB		EQ 5MG BASE	A203659	002	Apr 16, 2015	Mar	NEWA
>A>	AB		EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar	NEWA
>A>	AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar	NEWA

NELARABINEINJECTABLE;IV (INFUSION)
ARRANON

>A>	+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar	CAHN
>D>	+	SMITHKLINE BEECHAM	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar	CAHN

NEOSTIGMINE METHYLSULFATESOLUTION;INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

		FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan	NEWA
			10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan	NEWA

NIFEDIPINECAPSULE;ORAL
NIFEDIPINE

>D>	AB	EMCURE PHARMS USA	10MG	A202644	001	Apr 25, 2013	Mar	CAHN
>D>	AB		20MG	A202644	002	Apr 25, 2013	Mar	CAHN
>A>	AB	HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar	CAHN
>A>	AB		20MG	A202644	002	Apr 25, 2013	Mar	CAHN

NIMODIPINECAPSULE;ORAL
NIMODIPINE

AB	+	BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008	Jan	CAHN
----	---	----------------------	------	---------	-----	--------------	-----	------

NINTEDANIBCAPSULE;ORAL
OFEV

>D>		BOEHRINGER INGELHEIM	100MG	N205832	001	Oct 15, 2014	Mar	CAIN
>D>	+		150MG	N205832	002	Oct 15, 2014	Mar	CAIN

NINTEDANIB ESYLATECAPSULE;ORAL
OFEV

>A>		BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar	CAIN
>A>	+		EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar	CAIN

NORETHINDRONETABLET;ORAL-28
NOR-QD

>A>	AB1	+	ACTAVIS LABS UT INC	0.35MG	N017060	001		Mar	CAHN
>D>	AB1	+	WATSON LABS (UTAH)	0.35MG	N017060	001		Mar	CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM;TOPICAL
MYKACET

>D>		@ G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Mar	CMFD
>A>	AT		100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Mar	CMFD

OINTMENT;TOPICAL
MYKACET

>D>		@ G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Mar	CMFD
>A>	AT		100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Mar	CMFD

OLANZAPINETABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB		MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015	Feb	NEWA
AB			10MG	A203044	002	Feb 20, 2015	Feb	NEWA
AB			15MG	A203044	003	Feb 20, 2015	Feb	NEWA
AB			20MG	A203044	004	Feb 20, 2015	Feb	NEWA
AB		ORCHID HLTHCARE	5MG	A202937	001	Mar 02, 2015	Feb	NEWA
AB			10MG	A202937	002	Mar 02, 2015	Feb	NEWA
AB			15MG	A202937	003	Mar 02, 2015	Feb	NEWA
AB			20MG	A202937	004	Mar 02, 2015	Feb	NEWA

OLAPARIBCAPSULE;ORAL
LYNPARZA

		ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Jan	CTNA
--	--	--------------------	------	---------	-----	--------------	-----	------

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
PAZEO

+ ALCON RES LTD EQ 0.7% BASE N206276 001 Jan 30, 2015 Jan NEWA

ONDANSETRONTABLET, ORALLY DISINTEGRATING;ORAL
ZOFRAN ODT

>D>	AB	GLAXOSMITHKLINE	4MG	N020781	001	Jan 27, 1999	Mar CAHN
>D>	AB	+	8MG	N020781	002	Jan 27, 1999	Mar CAHN
>A>	AB	NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar CAHN
>A>	AB	+	8MG	N020781	002	Jan 27, 1999	Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

@ TARO PHARMS IRELAND EQ 2MG BASE/ML

A078014 001 Mar 21, 2008 Jan DISC

ZOFRAN

>D>	AP	+	GLAXOSMITHKLINE	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar CAHN
>A>	AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar CAHN
ZOFRAN PRESERVATIVE FREE								
>D>	AP	+	GLAXOSMITHKLINE	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar CAHN
>A>	AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar CAHN

SOLUTION;ORAL

ZOFRAN

>D>	AA	+	GLAXOSMITHKLINE	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar CAHN
>A>	AA	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar CAHN

TABLET;ORAL

ZOFRAN

>D>	AB	GLAXOSMITHKLINE	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar CAHN
>D>	AB		EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar CAHN
>D>	AB	+	EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar CAHN
>A>	AB	NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar CAHN
>A>	AB		EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar CAHN
>A>	AB	+	EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar CAHN

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

NORFLEX

>D>	AP	+	MEDICIS	30MG/ML	N013055	001		Mar DISC
>A>		@		30MG/ML	N013055	001		Mar DISC

ORPHENADRINE CITRATE

>D>	AP	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar CRLD
>A>	AP	+	30MG/ML	A040484	001	May 24, 2006	Mar CRLD

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

>A>	AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar CAHN
>D>	AB	+	WATSON LABS (UTAH)	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar CAHN

GEL, METERED;TRANSDERMAL

GELNIQUE 3%

>A>		+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar CAHN
>D>		+	WATSON LABS INC	3%	N202513	001	Dec 07, 2011	Mar CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

>A>		+	ACTAVIS LABS UT INC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Mar CAHN
>D>		+	WATSON LABS	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Mar CAHN

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXAYDO

>A>		ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	Mar CTNA
>A>			7.5MG	N202080	002	Jun 17, 2011	Mar CTNA
>D>		OXECTA					
>D>		ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	Mar CTNA
>D>			7.5MG	N202080	002	Jun 17, 2011	Mar CTNA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar	NEWA
>A>	AB	VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar	NEWA
>A>	AB		20MG	A077712	005	Apr 13, 2015	Mar	NEWA

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Feb	CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Feb	CAHN

PALBOCICLIB

CAPSULE; ORAL

IBRANCE

PFIZER INC

+

			75MG	N207103	001	Feb 03, 2015	Feb	NEWA
			100MG	N207103	002	Feb 03, 2015	Feb	NEWA
	+		125MG	N207103	003	Feb 03, 2015	Feb	NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

>D>	@	ASTRAZENECA	1MG/ML	A072210	001	Mar 31, 1988	Mar	CAHN
>D>	@		2MG/ML	A072211	001	Mar 31, 1988	Mar	CAHN
>D>	@		2MG/ML	A072212	001	Mar 31, 1988	Mar	CAHN
>D>	@		2MG/ML	A072213	001	Mar 31, 1988	Mar	CAHN
>A>	@	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988	Mar	CAHN
>A>	@		2MG/ML	A072211	001	Mar 31, 1988	Mar	CAHN
>A>	@		2MG/ML	A072212	001	Mar 31, 1988	Mar	CAHN
>A>	@		2MG/ML	A072213	001	Mar 31, 1988	Mar	CAHN

>D> PANOBINOSTAT

>D> CAPSULE; ORAL

>D> FARYDAK

>D>		NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Mar	CPOT
			10MG	N205353	001	Feb 23, 2015	Feb	NEWA
>D>			15MG	N205353	002	Feb 23, 2015	Mar	CPOT
			15MG	N205353	002	Feb 23, 2015	Feb	NEWA
>D>	+		20MG	N205353	003	Feb 23, 2015	Mar	CPOT
	+		20MG	N205353	003	Feb 23, 2015	Feb	NEWA

>A> PANOBINOSTAT LACTATE

>A> CAPSULE; ORAL

>A> FARYDAK

>A>		NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar	CAIN
>A>			EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar	CPOT
>A>			EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar	CAIN
>A>			EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar	CPOT
>A>	+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar	CAIN
>A>	+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar	CPOT

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

>A>	AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar	CAHN
>A>	AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar	CAHN
>D>	AB	KUDCO IRELAND	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar	CAHN
>D>	AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar	CAHN

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

BANNER LIFE SCIENCES

AB			1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
AB			2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
AB			4MCG	A202539	003	Mar 27, 2014	Jan	CAHN

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

>D>	+	GLAXOSMITHKLINE	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar	CAHN
>D>			EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar	CAHN
>A>	+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar	CAHN

	TABLET;ORAL								
	VOTRIENT								
>A>		EQ 400MG BASE		N022465	002	Oct 19, 2009		Mar	CAHN
	<u>PENTOXIFYLLINE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	PENTOXIFYLLINE								
AB	VALEANT PHARMS	400MG		A075028	001	Jul 20, 1998		Feb	CAHN
	<u>PHENDIMETRAZINE TARTRATE</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	BONTRIL								
	@ VALEANT	105MG		A088021	001	Sep 21, 1982		Jan	DISC
	PHENDIMETRAZINE TARTRATE								
	+ SANDOZ	105MG		N018074	001			Jan	CTEC
	<u>PHENYLEPHRINE HYDROCHLORIDE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	PHENYLEPHRINE HYDROCHLORIDE								
	AKORN INC	2.5%		N207926	001	Jan 15, 2015		Jan	NEWA
		10%		N207926	002	Jan 15, 2015		Jan	NEWA
	<u>PHENYTOIN SODIUM</u>								
	INJECTABLE;INJECTION								
	PHENYTOIN SODIUM								
AP	+ EUROHLTH INTL SARL	50MG/ML		A084307	001			Feb	CAHN
	<u>PILOCARPINE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	PILOCARPINE HYDROCHLORIDE								
>D>	AB	COREPHARMA	5MG	A076746	001	Nov 16, 2004		Mar	CAHN
>A>	AB	ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004		Mar	CAHN
	<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</u>								
	INJECTABLE;INJECTION								
	PIPERACILLIN AND TAZOBACTAM								
>D>	AP	AGILA SPECLTS	EQ 3MG BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014		Mar	CPOT
>A>	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014		Mar	CPOT
	<u>PIRBUTEROL ACETATE</u>								
	AEROSOL, METERED;INHALATION								
	MAXAIR								
	@ MEDICIS	EQ 0.2MG BASE/INH		N020014	001	Nov 30, 1992		Jan	DISC
	<u>PIRFENIDONE</u>								
	CAPSULE;ORAL								
	ESBRIET								
	+ GENENTECH INC	267MG		N022535	001	Oct 15, 2014		Feb	CAHN
	<u>PODOFILOX</u>								
	GEL;TOPICAL								
	CONDYLOX								
	+ ACTAVIS LABS UT INC	0.5%		N020529	001	Mar 13, 1997		Feb	CAHN
	SOLUTION;TOPICAL								
	CONDYLOX								
AT	+ ACTAVIS LABS UT INC	0.5%		N019795	001	Dec 13, 1990		Jan	CAHN
	<u>POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE</u>								
	FOR SOLUTION;ORAL								
	PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE								
>A>	AA	STRIDES ARCOLAB LTD	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A204559	001	Apr 13, 2015		Mar	NEWA
	<u>POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE								
AT	ALCON RES LTD	10,000 UNITS/ML;EQ 1MG BASE/ML		A064211	001	Apr 13, 1998		Jan	CAHN

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB2	MYLAN PHARMS INC	8MEQ	A204662	001	Aug 21, 2014	Feb	CPOT
AB2		10MEQ	A204662	002	Aug 21, 2014	Feb	CPOT

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb	CAHN
----	---	--------------------	----------------	---------	-----	--------------	-----	------

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

AB	BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan	CAHN
AB		200MG	A200900	002	Aug 16, 2013	Jan	CAHN

GEL;VAGINAL
CRINONE

ACTAVIS LABS UT INC 4%
+ 8%

N020701	001	Jul 31, 1997	Feb	CAHN
N020701	002	Jul 31, 1997	Feb	CAHN

INJECTABLE;INJECTION
PROGESTERONE

>A>	AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar	CAHN
>D>	AO	+	WATSON LABS (UTAH)	50MG/ML	N017362	002		Mar	CAHN

PROMETHAZINE HYDROCHLORIDE

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

>D>	AB	EMCURE PHARMS USA	12.5MG	A040673	001	Mar 05, 2008	Mar	CAHN
>D>	AB		25MG	A040673	002	Mar 05, 2008	Mar	CAHN
>D>	AB		50MG	A040673	003	Mar 05, 2008	Mar	CAHN
>A>	AB	HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar	CAHN
>A>	AB		25MG	A040673	002	Mar 05, 2008	Mar	CAHN
>A>	AB		50MG	A040673	003	Mar 05, 2008	Mar	CAHN

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

AB	WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan	NEWA
----	-----------------	------	---------	-----	--------------	-----	------

ROFLUMILAST

TABLET;ORAL

DALIRESP

>A>	+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011	Mar	CAHN
>D>	+	FOREST RES INST INC	500MCG	N022522	001	Feb 28, 2011	Mar	CAHN

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
SCOPOLAMINE

>A>	AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar	CAHN
>D>	AB	PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Mar	CAHN
	AB		1MG/72HR	A078830	001	Jan 30, 2015	Jan	NEWA
		TRANSDERM SCOP						
AB	+	NOVARTIS	1MG/72HR	N017874	001		Jan	CFTG

SILDENAFIL CITRATE

SOLUTION;INTRAVENOUS
REVATIO

>D>	+	PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar	CFTG
>A>	AP	+	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar	CFTG
>A>		SILDENAFIL CITRATE						
>A>	AP	AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar	NEWA

SILODOSINCAPSULE;ORAL
RAPAFLO

>A>	+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar CAHN
>A>			8MG	N022206	002	Oct 08, 2008	Mar CAHN
>D>	+	WATSON LABS	4MG	N022206	001	Oct 08, 2008	Mar CAHN
>D>			8MG	N022206	002	Oct 08, 2008	Mar CAHN

SODIUM CHLORIDEINJECTABLE;INJECTION
SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb CAHN
		SODIUM CHLORIDE 0.9%					
		EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+	LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CAHN
			112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CAHN
	+		405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CPOT
			1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CPOT

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP		PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb NEWA
----	--	-------------------	--------------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATEPOWDER;ORAL, RECTAL
KALEXATE

>A>		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015	Mar NEWA
-----	--	----------	----------	---------	-----	--------------	----------

SOMATROPIN RECOMBINANTINJECTABLE;INJECTION
NORDITROPIN FLEXPRO

		NOVO NORDISK INC	30MG/3ML	N021148	011	Jan 23, 2015	Jan NEWA
		NORDITROPIN NORDIFLEX					
>D>	@	NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009	Mar CMFD
>A>			30MG/3ML	N021148	007	Mar 10, 2009	Mar CMFD
	@		30MG/3ML	N021148	007	Mar 10, 2009	Jan DISC
		NUTROPIN					
>D>	+	GENENTECH	10MG/VIAL	N020168	002	Nov 17, 1993	Mar CTEC
>A> BX	+		10MG/VIAL	N020168	002	Nov 17, 1993	Mar CTEC
>D>		TEV-TROPIN					
>D> BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar CTNA
>A>		ZOMACTON					
>A> BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar CTNA
>A> BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar NEWA

SOTALOL HYDROCHLORIDETABLET;ORAL
BETAPACE

>D> AB1		BAYER HLTHCARE	80MG	N019865	001	Oct 30, 1992	Mar CAHN
>D> AB1			120MG	N019865	005	Apr 20, 1994	Mar CAHN
>D> AB1	+		160MG	N019865	002	Oct 30, 1992	Mar CAHN
>D> AB1			240MG	N019865	003	Oct 30, 1992	Mar CAHN
>D>	@		320MG	N019865	004	Oct 30, 1992	Mar CAHN
>A> AB1		COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar CAHN
>A> AB1			120MG	N019865	005	Apr 20, 1994	Mar CAHN
>A> AB1	+		160MG	N019865	002	Oct 30, 1992	Mar CAHN
>A> AB1			240MG	N019865	003	Oct 30, 1992	Mar CAHN
>A>	@		320MG	N019865	004	Oct 30, 1992	Mar CAHN

SULFACETAMIDE SODIUMLOTION;TOPICAL
KLARON

>D> AB	+	VALEANT BERMUDA	10%	N019931	001	Dec 23, 1996	Mar CAHN
>A> AB	+	VALEANT PHARMS NORTH	10%	N019931	001	Dec 23, 1996	Mar CAHN
		SOLUTION/DROPS;OPHTHALMIC					
		SULFACETAMIDE SODIUM					
>D>	@	AKORN	10%	A040215	001	May 25, 1999	Mar CMFD
>A> AT			10%	A040215	001	May 25, 1999	Mar CMFD

TELAPREVIRTABLET; ORAL
INCIVEK

@ VERTEX PHARMS 375MG N201917 001 May 23, 2011 Jan DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

>A> TENOFOVIR DISOPROXIL FUMARATE

>A> AB TEVA PHARMS USA 300MG A091612 001 Mar 18, 2015 Mar NEWA
VIREAD

>D> + GILEAD SCIENCES INC 300MG N021356 001 Oct 26, 2001 Mar CFTG

>A> AB + 300MG N021356 001 Oct 26, 2001 Mar CFTG

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

@ WOCKHARDT EQ 250MG BASE A078229 001 Jul 02, 2007 Feb DISC

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

AB1 ABBVIE 25MG/2.5GM PACKET N021015 001 Feb 28, 2000 Jan CTEC

AB1 + 50MG/5GM PACKET N021015 002 Feb 28, 2000 Jan CTEC

TESTIM

AB2 + AUXILIUM PHARMS 50MG/5GM PACKET N021454 001 Oct 31, 2002 Jan CTEC

TESTOSTERONE

>A> @ ACTAVIS LABS UT INC 1% (2.5GM/PACKET) A076737 001 Jan 27, 2006 Mar CAHN

>A> @ 1% (5GM/PACKET) A076737 002 Jan 27, 2006 Mar CAHN

AB1 PERRIGO ISRAEL 25MG/2.5GM PACKET N203098 002 Jan 31, 2013 Jan CTEC

AB1 50MG/5GM PACKET N203098 003 Jan 31, 2013 Jan CTEC

>D> @ WATSON LABS 1% (2.5GM/PACKET) A076737 001 Jan 27, 2006 Mar CAHN

>D> @ 1% (5GM/PACKET) A076737 002 Jan 27, 2006 Mar CAHN

VOGELXO

AB2 UPSHER SMITH 50MG/5GM PACKET N204399 002 Jun 04, 2014 Jan CTEC

TETRABENAZINE

TABLET; ORAL

XENAZINE

VALEANT PHARMS NORTH 12.5MG N021894 001 Aug 15, 2008 Feb CAHN

+ 25MG N021894 002 Aug 15, 2008 Feb CAHN

THEOPHYLLINE

TABLET; ORAL

THEOLAIR

>D> + MEDICIS 125MG A086399 001 Mar DISC

>A> @ 125MG A086399 001 Mar DISC

>D> + 250MG A086399 002 Mar DISC

>A> @ 250MG A086399 002 Mar DISC

TOBRAMYCIN

SOLUTION; INHALATION

KITABIS PAK

AN PULMOFLOW INC 300MG/5ML N205433 001 Dec 02, 2014 Feb CTEC

SOLUTION/DROPS; OPHTHALMIC

TOBREX

>A> AT + ALCON LABS INC 0.3% N050541 001 Mar CAHN

>D> AT + FALCON PHARMS 0.3% N050541 001 Mar CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

>D> @ ASTRAZENECA EQ 10MG BASE/ML A063119 001 Oct 31, 1994 Mar CAHN

>D> @ EQ 40MG BASE/ML A063120 001 Oct 31, 1994 Mar CAHN

>D> @ EQ 40MG BASE/ML A063121 001 Oct 31, 1994 Mar CAHN

>D> @ EQ 40MG BASE/ML A063122 001 Oct 31, 1994 Mar CAHN

>A> @ IGI LABS INC EQ 10MG BASE/ML A063119 001 Oct 31, 1994 Mar CAHN

>A> @ EQ 40MG BASE/ML A063120 001 Oct 31, 1994 Mar CAHN

>A> @ EQ 40MG BASE/ML A063121 001 Oct 31, 1994 Mar CAHN

>A> @ EQ 40MG BASE/ML A063122 001 Oct 31, 1994 Mar CAHN

TOLCAPONE

TABLET; ORAL

TASMAR

>D>	+	VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar CFTG
>A>	AB	+	100MG	N020697	001	Jan 29, 1998	Mar CFTG
>A>		TOLCAPONE					
>A>	AB	PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar NEWA

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

AB		IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb NEWA
AB			2MG	A077006	002	Feb 23, 2015	Feb NEWA

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCAMTIN

>D>		GLAXO WELLCOME	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar CAHN	
>D>	+		EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar CAHN	
>A>		NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar CAHN	
>A>	+		EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar CAHN	
		INJECTABLE; INJECTION						
		HYCAMTIN						
>D>	AP	+	GLAXOSMITHKLINE	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar CAHN
>A>	AP	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar CAHN

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

@	EUROHLTH INTL SARL	20MG/2ML (10MG/ML)
@		50MG/5ML (10MG/ML)
@	LUITPOLD	20MG/2ML (10MG/ML)
@		50MG/5ML (10MG/ML)

A078007	001	Jun 11, 2008	Jan DISC
A078007	002	Jun 11, 2008	Jan DISC
A090656	001	Apr 21, 2010	Jan DISC
A090656	002	Apr 21, 2010	Jan DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

>D>		GLAXOSMITHKLINE LLC	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar CAHN
>D>			EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar CAHN
>D>	+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar CAHN
>A>		NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar CAHN
>A>			EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar CAHN
>A>	+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar CAHN

TRAZODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

>D>	+	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Mar DISC
>A>	@		150MG	N022411	001	Feb 02, 2010	Mar DISC
>D>			300MG	N022411	002	Feb 02, 2010	Mar DISC
>A>	@		300MG	N022411	002	Feb 02, 2010	Mar DISC

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIDERM

>A>	AT	CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar NEWA
>A>	AT		0.5%	A088042	003	Mar 25, 2015	Mar NEWA

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

>D>		@ G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar CMFD
>A>	AT		0.1%	A089129	001	Aug 14, 1986	Mar CMFD

OINTMENT; TOPICAL

KENALOG

>D>		@ DELCOR ASSET CORP	0.025%	N011600	003		Mar CMFD
>A>	AT		0.025%	N011600	003		Mar CMFD
>D>		@	0.1%	N011600	001		Mar CMFD
>A>	AT		0.1%	N011600	001		Mar CMFD

SPRAY; TOPICAL

KENALOG

>D>	+	RANBAXY	0.147MG/GM	N012104	001		Mar CFTG
>A>	AT	+	0.147MG/GM	N012104	001		Mar CFTG

	SPRAY; TOPICAL						
>A>	TRIAMCINOLONE ACETONIDE						
>A> AT	PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015	Mar	NEWA
	<u>TRIPTORELIN PAMOATE</u>						
	INJECTABLE; INTRAMUSCULAR						
	TRELSTAR						
+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Jan	CAHN
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Jan	CAHN
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Jan	CAHN
	<u>UNOPROSTONE ISOPROPYL</u>						
	SOLUTION/DROPS; OPHTHALMIC						
	RESCULA						
+	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Jan	CAHN
	<u>URSODIOL</u>						
	CAPSULE; ORAL						
	ACTIGALL						
>A>	@ ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987	Mar	CAHN
>A> AB	+	300MG	N019594	002	Dec 31, 1987	Mar	CAHN
>D>	@ WATSON PHARMS	150MG	N019594	001	Dec 31, 1987	Mar	CAHN
>D> AB	+	300MG	N019594	002	Dec 31, 1987	Mar	CAHN
	<u>VALACYCLOVIR HYDROCHLORIDE</u>						
	TABLET; ORAL						
	VALACYCLOVIR HYDROCHLORIDE						
>A> AB	HETERO LABS LTD V	EQ 1GM BASE	A203047	002	Apr 08, 2015	Mar	NEWA
>A> AB		EQ 500MG BASE	A203047	001	Apr 08, 2015	Mar	NEWA
	<u>VALPROIC ACID</u>						
	CAPSULE; ORAL						
	VALPROIC ACID						
AB	BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan	CAHN
	CAPSULE, DELAYED RELEASE; ORAL						
	STAVZOR						
	@ BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan	CAHN
	@	250MG	N022152	002	Jul 29, 2008	Jan	CAHN
	@	500MG	N022152	003	Jul 29, 2008	Jan	CAHN
	<u>VANCOMYCIN HYDROCHLORIDE</u>						
	CAPSULE; ORAL						
	VANCOMYCIN HYDROCHLORIDE						
AB	LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan	NEWA
AB		EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan	NEWA
	<u>VENLAFAXINE HYDROCHLORIDE</u>						
	CAPSULE, EXTENDED RELEASE; ORAL						
	VENLAFAXINE HYDROCHLORIDE						
AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb	CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb	CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb	CAHN
	<u>VERTEPORFIN</u>						
	INJECTABLE; INJECTION						
	VISUDYNE						
>A>	+ VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar	CAHN
>D>	+ VALEANT PHARMS INC	15MG/VIAL	N021119	001	Apr 12, 2000	Mar	CAHN
	<u>VILAZODONE HYDROCHLORIDE</u>						
	TABLET; ORAL						
	VIIBRYD						
>D>	+ FOREST LABS INC	10MG	N022567	001	Jan 21, 2011	Mar	CAHN
>D>		20MG	N022567	002	Jan 21, 2011	Mar	CAHN
>D>		40MG	N022567	003	Jan 21, 2011	Mar	CAHN
>A>	+ FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar	CAHN
>A>		20MG	N022567	002	Jan 21, 2011	Mar	CAHN
>A>		40MG	N022567	003	Jan 21, 2011	Mar	CAHN

ZAFIRLUKASTTABLET; ORAL
ACCOLATE

AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb	CAHN
AB	+	20MG	N020547	001	Sep 26, 1996	Feb	CAHN

ZOLEDRONIC ACIDINJECTABLE; IV (INFUSION)
ZOLEDRONIC ACID

>A>	AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar	NEWA
>D>	AP	USV NORTH AMERICA	EQ 4MG BASE/VIAL	A202923	001	Sep 04, 2014	Mar	CPOT
>A>	AP		EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CPOT

ZOLPIDEM TARTRATETABLET; ORAL
ZOLPIDEM TARTRATE

>D>	AB	HIKMA	5MG	A078129	001	Apr 30, 2008	Mar	DISC
>A>		@	5MG	A078129	001	Apr 30, 2008	Mar	DISC
>D>	AB		10MG	A078129	002	Apr 30, 2008	Mar	DISC
>A>		@	10MG	A078129	002	Apr 30, 2008	Mar	DISC

ZONISAMIDECAPSULE; ORAL
ZONISAMIDE

AB	BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan	CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan	CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan	CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL
SHADE UVAGUARD

>A>	+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992	Mar	CAHN
>D>	+	SCHERING PLOUGH	3%;7.5%;3%	N020045	001	Dec 07, 1992	Mar	CAHN

BUDESONIDE

SPRAY, METERED; NASAL
RHINOCORT ALLERGY

>A>	+	ASTRAZENECA PHARMS	0.032MG/SPRAY	N020746	003	Mar 23, 2015	Mar	NEWA
-----	---	--------------------	---------------	---------	-----	--------------	-----	------

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL
LOTRIMIN ULTRA

>A>	+	BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001	Mar	CAHN
>D>	+	SCHERING PLOUGH	1%	N021307	001	Dec 07, 2001	Mar	CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

		BANNER LIFE SCIENCES	5MG	N022429	001	Jul 23, 2009	Jan	CAHN
	+		10MG	N022429	004	Jul 23, 2009	Jan	CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

		BANNER LIFE SCIENCES	5MG	N022429	003	Jul 23, 2009	Jan	CAHN
	+		10MG	N022429	002	Jul 23, 2009	Jan	CAHN

TABLET, CHEWABLE; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

		JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015	Feb	NEWA
			10MG	A091116	002	Feb 19, 2015	Feb	NEWA
		SANDOZ	5MG	A078692	001	Feb 14, 2008	Feb	CTNA
	+		10MG	A078692	002	Feb 14, 2008	Feb	CTNA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

		JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015	Feb	NEWA
			10MG	A091116	004	Feb 19, 2015	Feb	NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

>A>	@	BAYER HEALTHCARE LLC	8MG	N007638	001		Mar	CAHN
>A>	+		12MG	N007638	002		Mar	CAHN
>D>	@	SCHERING PLOUGH	8MG	N007638	001		Mar	CAHN
>D>	+		12MG	N007638	002		Mar	CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

>A>	+	BAYER HEALTHCARE LLC	8MG;120MG	N018397	001		Mar	CAHN
>D>	+	SCHERING PLOUGH	8MG;120MG	N018397	001		Mar	CAHN

CLOTRIMAZOLE

CREAM; VAGINAL

GYNE-LOTRIMIN

>A>	+	BAYER HEALTHCARE LLC	1%	N018052	002	Nov 30, 1990	Mar	CAHN
>D>	+	SCHERING PLOUGH	1%	N018052	002	Nov 30, 1990	Mar	CAHN

GYNE-LOTRIMIN 3

>A>	+	BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998	Mar	CAHN
>D>	+	SCHERING PLOUGH	2%	N020574	001	Nov 24, 1998	Mar	CAHN

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN COMBINATION PACK

>A>	+	BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993	Mar	CAHN
>D>	+	SCHERING PLOUGH	1%,100MG	N020289	002	Apr 26, 1993	Mar	CAHN

TABLET; VAGINAL

GYNE-LOTRIMIN

>A>	+	BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990	Mar	CAHN
>D>	+	SCHERING PLOUGH	100MG	N017717	002	Nov 30, 1990	Mar	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER LIFE SCIENCES	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan CAHN
----------------------	---	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL	60MG;120MG	A090818	001	Jan 29, 2015	Jan NEWA
-------------------	------------	---------	-----	--------------	----------

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BANNER LIFE SCIENCES	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan CAHN
----------------------	--	---------	-----	--------------	----------

MIDOL LIQUID GELS

+ BANNER LIFE SCIENCES	200MG	N021472	001	Oct 18, 2002	Jan CAHN
------------------------	-------	---------	-----	--------------	----------

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH AND LOMB	EQ 0.035% BASE	N021996	002	Feb 11, 2015	Feb NEWA
-----------------	----------------	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES	1MG	N021855	001	Aug 04, 2005	Jan CAHN
----------------------	-----	---------	-----	--------------	----------

+ BANNER LIFE SCIENCES	2MG	N021855	002	Aug 04, 2005	Jan CAHN
------------------------	-----	---------	-----	--------------	----------

LORATADINE

CAPSULE;ORAL

CLARITIN

>A>	+ BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008	Mar CAHN
-----	------------------------	------	---------	-----	--------------	----------

>D>	+ SCHERING PLOUGH	10MG	N021952	001	Jun 16, 2008	Mar CAHN
-----	-------------------	------	---------	-----	--------------	----------

SYRUP;ORAL

CLARITIN

>A>	+ BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002	Mar CAHN
-----	------------------------	--------	---------	-----	--------------	----------

>D>	+ SCHERING PLOUGH	1MG/ML	N020641	002	Nov 27, 2002	Mar CAHN
-----	-------------------	--------	---------	-----	--------------	----------

CLARITIN HIVES RELIEF

>A>	@ BAYER HEALTHCARE LLC	1MG/ML	N020641	003	Nov 19, 2003	Mar CAHN
-----	------------------------	--------	---------	-----	--------------	----------

>D>	@ SCHERING PLOUGH	1MG/ML	N020641	003	Nov 19, 2003	Mar CAHN
-----	-------------------	--------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

>A>	+ BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006	Mar CAHN
-----	------------------------	-----	---------	-----	--------------	----------

>D>	+ SCHERING PLOUGH	5MG	N021891	001	Aug 23, 2006	Mar CAHN
-----	-------------------	-----	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

CLARITIN REDITABS

>A>	+ BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006	Mar CAHN
-----	------------------------	-----	---------	-----	--------------	----------

>D>	+ SCHERING PLOUGH	5MG	N021993	001	Dec 12, 2006	Mar CAHN
-----	-------------------	-----	---------	-----	--------------	----------

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D

>A>	+ BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002	Mar CAHN
-----	------------------------	-----------	---------	-----	--------------	----------

>D>	+ SCHERING PLOUGH	5MG;120MG	N019670	002	Nov 27, 2002	Mar CAHN
-----	-------------------	-----------	---------	-----	--------------	----------

CLARITIN-D 24 HOUR

>A>	+ BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002	Mar CAHN
-----	------------------------	------------	---------	-----	--------------	----------

>D>	+ SCHERING PLOUGH	10MG;240MG	N020470	002	Nov 27, 2002	Mar CAHN
-----	-------------------	------------	---------	-----	--------------	----------

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BANNER LIFE SCIENCES	EQ 200MG BASE	N021920	001	Feb 17, 2006	Jan CAHN
------------------------	---------------	---------	-----	--------------	----------

CATALENT	EQ 200MG BASE	A202807	001	Feb 13, 2015	Feb NEWA
----------	---------------	---------	-----	--------------	----------

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX

>D>	IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009	Mar	DISC
>A>	@	EQ 2MG BASE	A076880	001	Feb 18, 2009	Mar	DISC
>D>		EQ 4MG BASE	A077850	001	Feb 18, 2009	Mar	DISC
>A>	@	EQ 4MG BASE	A077850	001	Feb 18, 2009	Mar	DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
ZEGERID OTC

>A>	+ BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009	Mar	CAHN
>D>	+ MSD CONSUMER	20MG;1.1GM	N022281	001	Dec 01, 2009	Mar	CAHN

FOR SUSPENSION;ORAL
ZEGERID OTC

>A>	+ BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Mar	CAHN
>D>	+ MSD CONSUMER	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Mar	CAHN

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OCUCLEAR

>A>	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	Mar	CAHN
>D>	SCHERING PLOUGH	0.025%	N018471	001	May 30, 1986	Mar	CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
MIRALAX

>A>	+ BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006	Mar	CAHN
>D>	+ SCHERING PLOUGH	17GM/SCOOPFUL	N022015	001	Oct 06, 2006	Mar	CAHN
	POLYETHYLENE GLYCOL 3350						
	RARITAN PHARMS INC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Jan	CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
RANITIDINE HYDROCHLORIDE

@	WOCKHARDT	EQ 75MG BASE	A078884	001	Jul 31, 2008	Jan	DISC
---	-----------	--------------	---------	-----	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 1 MARCH 2015

NO MARCH 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001					>A> D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001					>A> D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	>A> 8980319	Dec 21, 2030	DP			
	>A> 8992975	May 16, 2032	DP			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	>A> 8952065	Feb 10, 2035	U-1373			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	>A> 8936800	Dec 23, 2022	DP U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001					>A> NP	Mar 12, 2018
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	>A> 5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	>A> 5006528	Oct 20, 2014	DS DP U-761			
	>A> 5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 005					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021866 001	>A> 5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	>A> 5006528	Oct 20, 2014	DS DP U-763			
	>A> 5006528*PED	Apr 20, 2015				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	>A> 5006528	Oct 20, 2014	DS DP U-543			
	>A> 5006528	Oct 20, 2014	DS DP U-1632			
	>A> 5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	>A> 5006528	Oct 20, 2014	DS DP U-543			
	>A> 5006528	Oct 20, 2014	DS DP U-1632			
	>A> 5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	>A> 5006528	Oct 20, 2014	DS DP U-543			
	>A> 5006528	Oct 20, 2014	DS DP U-1632			
	>A> 5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	>A> 5006528	Oct 20, 2014	DS DP U-543			
	>A> 5006528	Oct 20, 2014	DS DP U-1632			
	>A> 5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		>A> M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			>A> NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		>A> PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			>A> PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		>A> M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			>A> NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		>A> PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			>A> PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATAZANAVIR SULFATE; COBICICISTAT - EVOTAZ</u>						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001 >A>	7112592	Feb 24, 2022	DS DP U-282			
>A>	7612087	Nov 12, 2026	DP			
>A>	8178554	Jul 24, 2021	DS DP U-282			
>A>	8471025	Aug 12, 2031	DS			
>A>	8835455	Oct 08, 2030	DP			
>A>	8969566	Jun 15, 2032	DS			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001 >A>	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
>A>	8163723	Aug 29, 2023	U-81			
>A>	8163723	Aug 29, 2023	U-644			
>A>	8163723	Aug 29, 2023	U-707			
>A>	8163723	Aug 29, 2023	U-1667			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8937062	Nov 13, 2029	U-80			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939	Y		
	7388029	Jan 21, 2022	U-938	Y		
>A>	8541466	Jan 31, 2021	U-1217			
>A>	8986715	Jan 15, 2023	U-1217			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003 >A>	6875445	Jul 30, 2021	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP ODE	Jan 09, 2018 Jan 09, 2022
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	>A> 8968753	Mar 14, 2034	U-1672			
	>A> 8968753	Mar 14, 2034	U-1673			
<u>CELECOXIB - CELECOXIB</u>						
A 076898 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 004					PC	Jun 02, 2015
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					>A> ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					>A> ODE	Mar 17, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Feb 01, 2028	U-1356			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Feb 01, 2028	U-1357			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898 001					>A> PC	Jul 01, 2015
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	>A> 8962000	Aug 31, 2025	DP U-1410			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	>A> 8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	8962680	Oct 31, 2031	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001					ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001					>A> M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002					>A> M-157	Mar 11, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	6037157	Jun 26, 2016			U-1635	
	6703403	Jun 26, 2016			U-1635	
	7148359	Jul 19, 2019		DP		
	7364752	Nov 10, 2020		DP		
	8188104	May 17, 2029	DS DP		U-1636	
	8268349	Aug 25, 2024		DP		
	8399015	Aug 25, 2024		DP		
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032			U-1637	
	8492386	Sep 04, 2032			U-1637	
	8501238	Sep 17, 2028	DS DP		U-1636	
	8642538	Sep 10, 2029	DS DP		U-1638	
	8680106	Sep 04, 2032			U-1637	
	8685984	Sep 04, 2032			U-1637	
	8686026	Jun 09, 2031		DP		
	8691938	Apr 13, 2032	DS DP			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					>A> ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					>A> ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					>A> ODE	Jan 23, 2020
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	>A> 8962000	Aug 31, 2025		DP	U-1412	
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS		U-860	
	6673838	Mar 01, 2022	DS		U-1364	
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020			U-1205	
	8088407	Oct 20, 2020			U-1205	
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019			U-1472	
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032		DP		
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032		DP		
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032			U-421	
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032		DP		
	8648106*PED	Jul 04, 2032				
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	>A> 8999387	Apr 23, 2030			U-55	
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	>A> 8999387	Apr 23, 2030			U-55	
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026			U-436	
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079	Jun 18, 2019		DP		
	8946292	Mar 22, 2027			U-1659	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	5061703	Oct 11, 2015	U-1641			
	5061703*PED	Apr 11, 2016				
	8058291	Dec 05, 2029	U-1641			
	8168209	May 22, 2026	DP			
	8168209*PED	Nov 22, 2026				
	8173708	May 22, 2026	U-1641			
	8173708*PED	Nov 22, 2026				
	8283379	May 22, 2026	U-1641			
	8283379*PED	Nov 22, 2026				
	8293794	Nov 22, 2025	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703	Oct 11, 2015	U-1641			
	5061703*PED	Apr 11, 2016				
	8039009	Sep 24, 2029	U-1641			
	8039009*PED	Mar 24, 2030				
	8058291	Dec 05, 2029	U-1641			
	8168209	May 22, 2026	DP			
	8168209*PED	Nov 22, 2026				
	8173708	May 22, 2026	U-1641			
	8173708*PED	Nov 22, 2026				
	8283379	May 22, 2026	U-1641			
	8283379*PED	Nov 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	May 22, 2026	DP			
	8329752*PED	Nov 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	May 22, 2026	U-1641			
	8362085*PED	Nov 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	May 22, 2026	DP			
	8598233*PED	Nov 22, 2026				
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	>A> 8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	>A> 8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	>A> 5747498	Nov 08, 2018	DS DP U-659		>A> I-671	May 14, 2016
	>A> 5747498*PED	May 08, 2019			>A> PED	Nov 14, 2016
	>A> 6900221	Nov 09, 2020	DS DP U-659			
	>A> 6900221	Nov 09, 2020	DS DP U-875			
	>A> 6900221	Nov 09, 2020	DS DP U-1046			
	>A> 6900221	Nov 09, 2020	DS DP U-1403			
	>A> 6900221*PED	May 09, 2021				
	>A> 7087613	Nov 09, 2020	U-659			
	>A> 7087613	Nov 09, 2020	U-1045			
	>A> 7087613	Nov 09, 2020	U-1403			
	>A> 7087613*PED	May 09, 2021				
	>A> RE41065	Nov 08, 2018	DS DP			
	>A> RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	>A> 5747498	Nov 08, 2018	DS DP U-659		>A> I-671	May 14, 2016
	>A> 5747498*PED	May 08, 2019			>A> PED	Nov 14, 2016
	>A> 6900221	Nov 09, 2020	DS DP U-659			
	>A> 6900221	Nov 09, 2020	DS DP U-875			
	>A> 6900221	Nov 09, 2020	DS DP U-1046			
	>A> 6900221	Nov 09, 2020	DS DP U-1403			
	>A> 6900221*PED	May 09, 2021				
	>A> 7087613	Nov 09, 2020	U-659			
	>A> 7087613	Nov 09, 2020	U-1045			
	>A> 7087613	Nov 09, 2020	U-1403			
	>A> 7087613*PED	May 09, 2021				
	>A> RE41065	Nov 08, 2018	DS DP			
	>A> RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	>A> 5747498	Nov 08, 2018	DS DP U-659		>A> I-671	May 14, 2016
	>A> 5747498*PED	May 08, 2019			>A> PED	Nov 14, 2016
	>A> 6900221	Nov 09, 2020	DS DP U-659			
	>A> 6900221	Nov 09, 2020	DS DP U-875			
	>A> 6900221	Nov 09, 2020	DS DP U-1046			
	>A> 6900221	Nov 09, 2020	DS DP U-1403			
	>A> 6900221*PED	May 09, 2021				
	>A> 7087613	Nov 09, 2020	U-659			
	>A> 7087613	Nov 09, 2020	U-1045			
	>A> 7087613	Nov 09, 2020	U-1403			
	>A> 7087613*PED	May 09, 2021				
	>A> RE41065	Nov 08, 2018	DS DP			
	>A> RE41065*PED	May 08, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001 >A>	8901349	Feb 18, 2024	U-1577			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLXACIN - XTORO</u>						
N 206307 001 >A>	6133260	Apr 12, 2017	DS DP			
	>A> 6432948	Apr 12, 2017	DS DP			
	>A> 8536167	Aug 08, 2031	U-1679			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001					>A> M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					>A> M-155	Mar 27, 2018
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 001					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 002					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 003					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 004					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001					>A> M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002					>A> M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003					>A> M-154	Mar 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	004				>A> M-154	Mar 18, 2018
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001	8497277	Dec 28, 2026	U-1456	I-702	Jan 29, 2018
		8497277	Dec 28, 2026	U-1491	ODE	Jan 29, 2022
		8497277	Dec 28, 2026	U-1650		
	>A>	8957079	Dec 28, 2026	DS DP		
<u>IDELALISIB - ZYDELIG</u>						
N 205858	001	>A> 8980901	May 12, 2025	U-1678		
<u>IDELALISIB - ZYDELIG</u>						
N 205858	002	>A> 8980901	May 12, 2025	U-1678		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	001	>A> 8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	002	>A> 8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	003	>A> 8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	004	>A> 8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	005	>A> 8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	006	>A> 8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	007	>A> 8999638	Oct 28, 2030	U-1674		
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	001	>A> 8992982	Apr 23, 2030	DP		
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	002	>A> 8992982	Apr 23, 2030	DP		
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986	005	8920383	Jul 17, 2026	DP		
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536	005	8920383	Jul 17, 2026	DP		
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081	002	>A> 8992486	Jun 05, 2024	DP		
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538	001	>A> 7918833	Sep 23, 2027	DP	NP	Feb 25, 2018
		>A> 7918833*PED	Mar 23, 2028			
		>A> 8512297	Sep 15, 2024	DP		
		>A> 8556864	Mar 03, 2024	DP		
		>A> 8603044	Mar 02, 2024	DP		
		>A> 8679069	Apr 12, 2025	DP		
		>A> 8992486	Jun 05, 2024	DP		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629	003	>A> 8992486	Jun 05, 2024	DP		
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454	001	5310912	Feb 25, 2016	DS		
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500	001	>A> 6812238	Oct 31, 2020	DS	>A> NCE	Mar 06, 2020
		>A> 7459561	Oct 31, 2020	DS	>A> GAIN	Mar 06, 2025
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501	001	>A> 6812238	Oct 31, 2020	DS	>A> NCE	Mar 06, 2020
		>A> 7459561	Oct 31, 2020	DS	>A> GAIN	Mar 06, 2025
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	001	8952064	Sep 21, 2021	DP		
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951	002	8952064	Sep 21, 2021	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	>A> 7435427	Sep 21, 2021	DP			
	>A> 8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	>A> 7435427	Sep 21, 2021	DP			
	>A> 8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	>A> 7495103	May 20, 2027	DS DP			
	>A> 8324242	Apr 18, 2027	U-1311			
	>A> 8354427	Jul 06, 2026	U-1311			
	>A> 8410274	Dec 28, 2026	DP			
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 8883206	Feb 27, 2033	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	>A> 7495103	May 20, 2027	DS DP			
	>A> 8324242	Apr 18, 2027	U-1311			
	>A> 8354427	Jul 06, 2026	U-1311			
	>A> 8410274	Dec 28, 2026	DP			
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 8883206	Feb 27, 2033	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018	U-1631			
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024	U-1662			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	>A> 8992952	Aug 05, 2024	DP			
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					>A> PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001					>A> D-147	Mar 23, 2018
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003					>A> D-147	Mar 23, 2018
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	>A> 5905082	May 18, 2016	DS DP		>A> D-147	Mar 23, 2018
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-1663			
	7435734	Oct 21, 2022	U-1663			
	7754731	Mar 11, 2029	DS DP U-1663			
	7820660	Apr 25, 2023	DS			
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					>A> PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					>A> PC	Sep 28, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 003					>A> PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 004					>A> PC	Sep 28, 2015
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	>A> 8980327	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	>A> 8980327	Dec 01, 2030	DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001					I-706	Feb 17, 2018
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002					I-706	Feb 17, 2018
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003					I-706	Feb 17, 2018
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004					I-706	Feb 17, 2018
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005					I-706	Feb 17, 2018
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	>A> 5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	>A> 7429559	Jan 13, 2019	DP			
	>A> 8815801	Jun 28, 2022	DP			
	>A> 8921326	Feb 05, 2031	DP U-1666			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004					M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001					>A> M-156	Mar 12, 2018
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	>A> 8163306	Sep 03, 2027	DP			
	>A> 8425938	Feb 22, 2026	DP			
	>A> 8431156	Oct 31, 2027	DP			
	>A> 8470367	Jun 30, 2024	DP			
	>A> 8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	>A> 8163306	Sep 03, 2027	DP			
	>A> 8425938	Feb 22, 2026	DP			
	>A> 8431156	Oct 31, 2027	DP			
	>A> 8470367	Jun 30, 2024	DP			
	>A> 8535717	Feb 22, 2026	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	>A> 9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	>A> 9006289	Oct 03, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	>A> 9006289	Oct 03, 2032	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8933030	Feb 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8933030	Feb 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	>A> 8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	>A> 8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	>A> 8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	>A> 8673927	May 04, 2027	U-1503			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	>A> 8846618	Jun 27, 2022	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP	U-1255		
	6458924	Aug 22, 2017	DS DP	U-1255		
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 3026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	>A> 8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					I-703	Jan 30, 2018
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS	U-1317		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS	U-1317		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS	U-1317		
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	>A> 8980881	Dec 20, 2025	U-1252			
	>A> 8980881	Dec 20, 2025	U-1253			
	>A> 8980881	Dec 20, 2025	U-1254			
	>A> 8980881	Dec 20, 2025	U-1255			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	>A> 8955512	Oct 26, 2021	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	>A> 8980931	Apr 28, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001 >A>	8956649	Feb 15, 2031	DP U-1665			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	8946276	Jun 28, 2032	U-1664			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028	U-1643			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001 >A>	7699609	Mar 29, 2022	DP			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP U-702			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	8623418	Nov 07, 2029	U-1640			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	8926594	Mar 31, 2026	DP			
	>A> 8939943	Feb 28, 2031	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	8969369	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	8969369	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	8969369	May 10, 2022	DP U-1556			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001 >A>	6060499	Aug 14, 2017	DP U-867			
	>A> 6060499*PED	Feb 14, 2018				
	>A> 6586458	Aug 14, 2017	DP U-867			
	>A> 6586458*PED	Feb 14, 2018				
	>A> 7332183	Oct 02, 2025	DP U-867			
	>A> 7332183*PED	Apr 02, 2026				
	>A> 8022095	Aug 14, 2017	DP U-867			
	>A> 8022095*PED	Feb 14, 2018				
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8951969	Nov 18, 2030	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8940772	Apr 30, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8940772	Apr 30, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001 >A>	7989474	Apr 06, 2024	U-1677			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002 >A>	7989474	Apr 06, 2024	U-1677			
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001 >A>	8791154	May 19, 2032	DP U-1680		NP PED	Jan 30, 2018 Jul 30, 2018
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031	U-1644			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007					M-153	Apr 16, 2016
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001 >A>	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	>A> 6833384	Sep 30, 2021	DS DP	U-1669	>A> ODE	Feb 23, 2022
	>A> 7067551	Aug 31, 2021	U-1669			
	>A> 7989494	Jan 17, 2028	DS DP			
	>A> 8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002 >A>	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	>A> 6833384	Sep 30, 2021	DS DP	U-1669	>A> ODE	Feb 23, 2022
	>A> 7067551	Aug 31, 2021	U-1669			
	>A> 7989494	Jan 17, 2028	DS DP			
	>A> 8883842	Jun 13, 2028	U-1669			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	>A> 6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	>A> 6833384	Sep 30, 2021	DS DP	U-1669	>A> ODE	Feb 23, 2022
	>A> 7067551	Aug 31, 2021		U-1669		
	>A> 7989494	Jan 17, 2028	DS DP			
	>A> 8883842	Jun 13, 2028		U-1669		
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP	U-904		
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	>A> 7696236	Dec 18, 2027		U-1601		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8946252	Jul 24, 2029		U-1481		
	8969398	Oct 02, 2029		U-1481		
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2016	DS DP	U-1115		
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019		U-1101		
	8952062	Dec 22, 2019		U-1102		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8920383	Jul 17, 2026		DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8920383	Jul 17, 2026		DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8920383	Jul 17, 2026		DP		
<u>SPINOSAD - NATROBA</u>						
N 022408 001	>A> 6063771	Jul 25, 2023	DP	U-1670	M-152	Nov 30, 2017
<u>SUMATRIPTAN SUCCINATE - ZECURITY</u>						
N 022278 001	>A> 8983594	Nov 19, 2030		DP	U-1328	
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	>A> 5789379	Apr 14, 2016	DS DP	U-1320		
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	>A> 8993520	Jun 02, 2026		U-1390		
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028		DP		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	>A> 8992989	Nov 16, 2027		DP	U-1675	
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	>A> 8992989	Nov 16, 2027		DP	U-1675	
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	>A> 8992989	Nov 16, 2027		DP	U-1675	
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	>A> 8992989	Nov 16, 2027		DP	U-1675	
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025		DP	U-1182	
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8962603	Jun 12, 2030		U-1657		
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001					>A> D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002					>A> D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003					>A> D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	>A> 8969355	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	>A> 8969355	Jun 15, 2027		U-1668		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	>A> 8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	>A> 8969355	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>